The Role Of Pparγ In Placental Development And Disease

Leena Kadam
Wayne State University,
THE ROLE OF PPARγ IN PLACENTAL DEVELOPMENT AND DISEASE

by

LEENA KADAM

DISSERTATION

Submitted to the Graduate School

of Wayne State University,

Detroit, Michigan

in partial fulfillment of the requirements

for the degree of

DOCTOR OF PHILOSOPHY

2017

MAJOR: PHYSIOLOGY

Approved By:

________________________________________
Advisor Date

________________________________________

________________________________________

________________________________________

________________________________________
ACKNOWLEDGEMENTS

I want to start by expressing my deepest gratitude to my mentor Dr. Sascha Drewlo for his continuous support and guidance throughout this journey. This would not have been possible without your patience and encouragement. It was an honor being your student.

I want to thank my graduate committee, Dr. Randall D Armant, Dr. Steven Cala, Dr. Robert Lasley, Dr. Fei Sun and Dr. Maik Huttemann for their expert opinion, constructive criticism and encouragement during this time.

I wish to thank the department of Physiology for giving me the opportunity to be a part of this prestigious department and especially Christine Cupps for being ever-so helpful and understanding about everything I have approached her for.

I would like to thank my colleagues Chandni Jain, Brian Kilburn and Hamid Reza Kohan-Ghadr for their help and support throughout the past 3 years. Thank you for having my back and standing up for me when I couldn’t.

I would also like to thank my collaborators Dr. Nardhy Gomez-Lopez, Dr. Randall D Armant, Dr. John Kingdom and Dora Baczyk for allowing me to work in your laboratories, your expert input and time.

Lastly, I would like to thank my family and friends for their immense patience and incessant support even when I didn’t deserve it. It is your love that makes my world turn!
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acknowledgements</td>
<td>ii</td>
</tr>
<tr>
<td>List of Tables</td>
<td>vii</td>
</tr>
<tr>
<td>List of Figures</td>
<td>viii</td>
</tr>
<tr>
<td>List of Abbreviations</td>
<td>x</td>
</tr>
<tr>
<td>Chapter 1 - Introduction</td>
<td>1</td>
</tr>
<tr>
<td>Anatomy of the human placenta:</td>
<td>1</td>
</tr>
<tr>
<td>Development of the human placenta:</td>
<td>2</td>
</tr>
<tr>
<td>Human placental trophoblast lineages and their functions:</td>
<td>3</td>
</tr>
<tr>
<td>Diseases associated with placental development:</td>
<td>5</td>
</tr>
<tr>
<td>Peroxisome proliferator-activated receptor transcription factors family</td>
<td>6</td>
</tr>
<tr>
<td>Peroxisome proliferator-activated receptor-gamma (PPAR(\gamma))</td>
<td>7</td>
</tr>
<tr>
<td>Chapter 2 - PPAR(\gamma) Prevents Inflammation Induced Preterm Birth by Attenuating Both Systemic and Local Inflammatory Pathways</td>
<td>16</td>
</tr>
<tr>
<td>Introduction</td>
<td>16</td>
</tr>
<tr>
<td>Materials and Methods</td>
<td>18</td>
</tr>
<tr>
<td>Animal treatments</td>
<td>18</td>
</tr>
<tr>
<td>Fetal and placenta weights</td>
<td>20</td>
</tr>
<tr>
<td>Chemokine/cytokine serum concentrations</td>
<td>20</td>
</tr>
<tr>
<td>Macrophage isolation from murine myometrial and decidual tissues</td>
<td>21</td>
</tr>
<tr>
<td>RNA isolation, cDNA synthesis, and qRT-PCR</td>
<td>22</td>
</tr>
<tr>
<td>Immunofluorescence</td>
<td>23</td>
</tr>
<tr>
<td>Statistical analysis</td>
<td>23</td>
</tr>
<tr>
<td>Results</td>
<td>24</td>
</tr>
<tr>
<td>Rosiglitazone treatment reduced the rate of LPS-induced preterm birth and stillbirth</td>
<td>24</td>
</tr>
</tbody>
</table>
Tissue collection .................................................................................................................... 53
First trimester explant culture ................................................................................................ 54
Cell Culture ............................................................................................................................ 54
Explants and cell culture treatments ...................................................................................... 54
RNA extraction and real time PCR ....................................................................................... 55
Protein extraction and western blotting ................................................................................. 56
Enzyme Linked Immunosorbent Assay ................................................................................. 57
Immunohistochemistry .......................................................................................................... 57
Matrigel invasion assay ......................................................................................................... 59
TUNEL assay ......................................................................................................................... 60
Results ....................................................................................................................................... 60
Rosiglitazone reduced endotoxin induced cytokine secretion ............................................... 60
Rosiglitazone reduced endotoxin induced apoptosis and restored proliferation .............. 61
Rosiglitazone reversed endotoxin mediated reduction in trophoblast differentiation marker expression .......................................................................................................................... 63
Rosiglitazone reduced endotoxin induced trophoblast invasion to control levels ................ 64
Endotoxin exposure increased invasion in the trophoblast cell line HTR-8/SV neo .......... 65
Endotoxin exposure induced integrins switching in HTR-8/SV neo cells ......................... 67
Discussion ................................................................................................................................. 67
Chapter 5 - PPARγ Regulates Trophoblast Differentiation Via Glial Cell Missing -1 .......... 76
Introduction ............................................................................................................................... 76
Materials and Methods .............................................................................................................. 77
Cell culture and treatments .................................................................................................... 77
Chromatin Immunoprecipitation ........................................................................................... 77
RNA extraction and qPCR analysis ....................................................................................... 78
Results ....................................................................................................................................... 79

Gcm1 expression is differentially regulated by PPARγ agonist and antagonist .................. 79

PPARγ and active RNA polymerase II preferentially bind to Site I in the GCM1 promoter to regulates its expression ................................................................. 80

Discussion ................................................................................................................................. 81

Chapter 6 – Development of a Culture Model for Simultaneous Studyng PPARγ Mediated Regulation in Extra-Villous and Villous Trophoblast Lineage Differentiation ............................................................. 83

Introduction ............................................................................................................................... 83

Materials and Methods .............................................................................................................. 84

Tissue collection .................................................................................................................... 84

Placental explant culture ........................................................................................................ 84

Tissue dissection, RNA extraction and qPCR analysis ......................................................... 85

Immunohistochemistry .......................................................................................................... 86

Results ....................................................................................................................................... 87

The isolated EVT fractions enriched for EVT-specific markers ........................................... 88

PPARγ antagonist increased invasion ................................................................................ 88

Discussion ................................................................................................................................. 88

Appendix A IACUC Approval Letter ........................................................................................... 91

Appendix B IRB Approval Letter .................................................................................................. 92

Appendix C Copyright License Agreement for Chapter 1 ...................................................... 93

Appendix D Copyright License Agreement for Chapter 2 ..................................................... 94

Appendix E Copyright License Agreement for Chapter 3 ..................................................... 95

References ................................................................................................................................... 96

Abstract ..................................................................................................................................... 143

Autobiographical Statement .................................................................................................... 147
LIST OF TABLES

Table 1: List of primers sequences used for gene expression analysis in mouse decidual and myometrial macrophages. ................................................................. 22

Table 2: Sequences of primer used for gene expression in macrophages........................................ 38

Table 3: Trophoblast explants/cell treatment groups and names.................................................. 55

Table 4: List of primer sequences used for studying expression levels of trophoblast differentiation markers.................................................................................. 56

Table 5: Primer sequences used for gene expression analysis in JEG-3 cells............................... 79

Table 6: List of primer sequences for gene expression analysis in invaded and floating villous trophoblast ................................................................................. 86
LIST OF FIGURES

Figure 1: The anatomy of human placenta. ................................................................. 1
Figure 2: Development of human placental structures. .............................................. 2
Figure 3: PPARγ has been shown to be involved in multiple key metabolic pathways in placentation and pregnancy................................................................. 8
Figure 4: Rosiglitazone treatment reduces the rate of LPS-induced PTB and improves neonatal outcomes. .............................................................. 19
Figure 5: Rosiglitazone treatment attenuates the systemic inflammatory response induced by LPS. ............................................................................. 26
Figure 6: Rosiglitazone treatment reduces the mRNA expression of NfkB1, Tnf, and Il10 in decidual and myometrial macrophages. ........................................... 28
Figure 7: RSG treatment altered the protein expression of NF-κB, TNF, and IL-10 in myometrial macrophages. ................................................................. 29
Figure 8: Purity of isolated macrophages from decidual and myometrial tissues. .............. 39
Figure 9: Rosiglitazone downregulates LPS induced TLR4 expression. ......................... 41
Figure 10: Rosiglitazone recuses LPS mediated downregulation of NRF2 expression. ........ 43
Figure 11: Rosiglitazone rescued LPS mediated decrease in HO-1 expression ............... 45
Figure 12: Rosiglitazone treatment reduced the inflammatory cytokine secretion in first trimester human placental explants. ............................................................. 61
Figure 13: Rosiglitazone treatment reduced endotoxin induced apoptosis and increased proliferation. ............................................................... 62
Figure 14: Rosiglitazone reversed endotoxin mediated reduction in trophoblast differentiation marker expression. ......................................................... 64
Figure 15: Endotoxin increased invasion in 1st trimester human placenta after 24 hrs of treatment. .............................................. 65
Figure 16: Rosiglitazone reduced endotoxin induced invasion in trophoblast cell line HTR- 8/SV Neo. ................................................................. 66
Figure 17: Rosiglitazone prevented endotoxin mediated integrin switching in trophoblast cell line HTR- 8/SV Neo ......................................................... 73
Figure 18: Gcm1 expression correlates to PPARγ activation status. ............................... 79
Figure 19: Illustration for putative PPARγ binding sites in GCM1 promoter............................. 80

Figure 20: PPARγ activation led to preferential binding and enrichment of the binding site I in GCM1 promoter.......................................................... 81

Figure 21: Illustration showing the separation of VT and EVT parts from cultured explants. ........................................................................................................ 86

Figure 22: Immunohistochemistry for Ki-67 showed presence of proliferating cells in cultured explants............................................................................. 87

Figure 23: The extra-villous tissue fractions dissected out from matrigel inserts enriched for EVT markers. ......................................................................................... 88

Figure 24: PPARγ activation led to preferential binding and enrichment of the binding site I in GCM1 promoter............................................................... 89
LIST OF ABBREVIATIONS

PPARγ: Peroxisome proliferator-activated receptor gamma

IUGR: Intra-uterine growth restriction

GDM: Gestational diabetes mellitus

PE: Pre-eclampsia

PTB: Preterm birth

PTL: Preterm labor

NF-κB: Nuclear factor kappa B

sFLT: Soluble fms-like tyrosine kinase

IL: Interleukin

TNFα: Tumor necrosis factor alpha

STAT: Signal transducer and activator of transcription

AP1: Activator protein 1

GCM1: Glial cell missing 1

CG-β: Chorionic gonadotropin beta

TLR4: Toll like receptor 4
CHAPTER 1 – INTRODUCTION

(This chapter contains previously published material. See Appendix C)

Anatomy of the human placenta

Placenta in mammals is a transient organ that acts as the primary source of nutrition for the growing fetus during pregnancy (1, 3). A fully developed human placenta is a circular disc-like organ that is around 3-4cm in thickness and weighs approximately 500 grams. The gross structure of the placenta is depicted in Figure 1. The margins/ends of the placenta are marked by the chorionic plate (covered by the amnion) on the fetal side and the base plate on the maternal side. These plates fuse at the end of the disc structure of the placenta and form the fetal membranes that envelope the growing fetus. The space between these plates is called the inter-villous space which is filled with maternal blood and consists of the placental villi – tree-like structures that stem out from the chorionic plate. The placenta villi comprise the functional unit of the placenta and are primarily of two types: (i) the anchoring villi - that connected to the basal plate at their tips and anchor the placenta and (ii) the floating villi – that are not attached to the basal plate and remain floating in the intervillous space. The core of the placental villi consists of capillary vessels that unite at the base of the placenta to form the umbilical artery and vein. The villi bathe in the maternal blood that fills the intervillous space and thus absorb nutrients and exchange gases with the maternal blood.
Development of the human placenta

The placenta develops from the outer cells of the blastocyst known as trophectoderm cells (Figure 2A). The trophectoderm cells initiate implantation by attaching and eventually invading into the maternal endometrium (4). These cells proliferate and form the first wave of syncytiotrophoblast cells that invade into the maternal endometrium and embeds the blastocyst inside the uterine tissue on approximately 1 week after fertilization (Figure 2B). This layer of cells continues to proliferate. Around week 2, it starts forming fluid filled spaces called lacunae (Figure 2B). Over the next few weeks of development, these lacunae merge to form one continuous intervillous space. The walls of the lacunae stretch from fetal side to the maternal decidual tissue and are called trabeculae (Figure 2D). The trabeculae are essentially finger like projections of cytotrophoblast cell columns emerging from the embryonic side and are referred to as primary villi. Over the course of weeks 3-7, these villi are penetrated by the extra-embryonic mesenchyme pushing the cytotrophoblast cells towards the periphery, giving rise to secondary villi. The secondary villi also show presence of mesenchymal cells. These cells give rise to the connective tissue inside the villous core and are precursors of the endothelial cells required for vascularization of the villi. The secondary villi finally develop into tertiary (mesenchymal) villi that are covered with cytotrophoblasts and have a connective tissue core with developed placental blood vessels. The
basic structure of human placenta is thus established by week 8 (Figure 2D). In the coming weeks, the tertiary villi further undergo rounds of trophoblast sprouting and branching angiogenesis to form a network of terminal villi – the most prominent form of villi found in term placenta.

**Human placental trophoblast lineages and their functions**

The cytotrophoblast cells proliferate and differentiate towards two major lineages. The extra-villous trophoblast lineage that develops from the cytotrophoblast cell columns at the tips of anchoring villi and the villous trophoblast lineage that cover the floating villi (5, 6).

**Extra-villous trophoblast lineage (EVT)**

These cells are primarily invasive in nature. The proximal cells of the cytotrophoblast columns proliferate and differentiate towards this invasive lineage (7, 8). They secrete several extracellular matrix degrading enzymes such as - matrix metalloproteinase 9,3,7, gelatinases - that help to breakdown of extracellular matrix and aid in their invasion into the maternal endometrial tissue (9, 10). The EVT lineage differentiates into subtypes with specialized functions: the interstitial subtype invades the decidua and secretes extracellular matrix components that help in anchoring the placenta whereas the endovascular subtype is involved with remodeling of uterine arteries (11). The endovascular EVT’s migrate into the artery lumen and displace the endothelium and degrade the smooth muscle cells in the artery wall, which enables regulation of blood flow at the-placental site (10, 12).

The EVT cells also help evade the maternal immune mechanisms at the maternal- fetal interface (13, 14). They refrain from expressing major histocompatibility complex proteins HLA-A, HLA-B and HLA-D- which are major stimulators of T-cell mediated graft rejection process. They further express HLA-E which binds to CD94 receptors on the uterine natural killer (uNK) cells resulting in recognition of trophoblast cells as ‘self’, thus rendering the uNK
cells inactive (15-19). They are also implicated in preventing fetal rejection by suppressing the local immune responsiveness and impairing responses to immune-activating cytokines present in the placental bed (19).

**Villous trophoblast lineage (VT)**

The VT cells are in direct contact with the maternal blood and form the exchange surface (1). The VT must adapt to environmental changes to secure growth throughout pregnancy and ensure nutrient, gas and waste exchange, while generating the bulk of the placental hormones essential to facilitate growth throughout pregnancy (6). The cytotrophoblasts under the surface of the villi can undergo either a symmetrical or an asymmetrical cell division. Asymmetrical division results in the formation of a proliferative cell and a differentiating cell (20). These differentiating cells exit the cell cycle and undergo cell fusion to form the multinucleate syncytiotrophoblast/syncytium, the exchange surface (21). Over the course of the pregnancy, this layer undergoes apoptosis, is sloughed/shed off as syncytial knots and is constantly replenished by the underlying proliferative cytotrophoblast (22, 23). The VT comprises of two compartments, an outer multinucleate fused layer that acts as the exchange surface and a lower proliferating cytotrophoblast layer that maintains a balance of proliferative: differentiating cells (24). The process of proliferation, differentiation, fusion, apoptosis and shedding within the trophoblast layer is termed as “trophoblast turnover” which is crucial for VT function. In addition to nutrient and gas exchange, the VT cells also participate in immune functions by expressing pattern recognition receptors like TLR (toll-like receptors) and NLR (Nod-like receptors) that recognize and bind to sequences unique to, and expressed on, the surface of microorganisms (25). Thus, they also play an active role in control of pathogens that may compromise fetal wellbeing (26).
Diseases associated with placental development

Proper development of the VT and EVT trophoblast lineages is crucial for placental function and dysregulation in both lineages has been associated with placental insufficiency syndromes. Shallow invasion and reduced remodeling of uterine arteries will result in under-perfusion of the placenta. The reduced perfusion often translates into reduced exchange of nutrients resulting into growth restricted fetuses observed in intra-uterine growth restriction (IUGR). Incomplete remodeling of uterine spiral arteries results in high velocity-unsteady blood flow which leads to hypoxia-reperfusion injury in the placenta. These events expose the placental tissue to oxidative stress, trophoblast damage from shear stress and local thrombosis all associated with pathologies like PE (27, 28). These features can result in various disease phenotypes; one hallmark being the release of proteins such as soluble fms-like tyrosine kinase (sFLT) into the maternal circulation. sFLT is an anti-angiogenic factor secreted by trophoblast cells and elevated level of sFLT have been observed in both human and animal models of PE and is often used as a marker for PE (29, 30). In addition to abnormal trophoblast differentiation, elevated inflammation is a common feature observed in these pathologies (31-33). Increased placental inflammation due to oxidative stress and elevated placental cytokine release are both features associated with PE and IUGR placentae (31, 34, 35). Severe forms of these pathologies lead to preterm birth which is a leading cause of neonatal mortality and morbidity (2, 36, 37).

Currently, there is a lack of clear understanding the molecular pathways contributing to abnormal placental function. Despite a strong correlation between elevated inflammation and placental pathologies, the effects of inflammation on trophoblast differentiation have not been explored (33, 34, 38, 39). **Factors common to both processes, inflammation and trophoblast differentiation, could serve as molecular targets for therapeutic use.** In the current study, we evaluate the potential of the nuclear hormone receptor Peroxisome proliferator-activated receptor
(PPARγ) for development as a molecular target. PPARγ was chosen because it has been shown to be involved with multiple aspects of pregnancy and placental function, as outlined in the upcoming sections.

**Peroxisome proliferator-activated receptor transcription factors family**

Peroxisome proliferator-activated receptors (PPARs), a moniker owed to the early observation that stimulation of these proteins could induce the proliferation of peroxisomes in rodent hepatocytes, are transcription factors belonging to the nuclear hormone receptor superfamily (40). The spectrum of ligands which effectively target these receptors include endogenously expressed lipid-soluble molecules (e.g. prostacyclin, lysophosphatidic acid), and the thiazolidinedione family of pharmaceutical compounds (e.g. Rosiglitazone, Pioglitazone) (41, 42). Like other members of this receptor superfamily, the interaction of PPARs with their corresponding ligands elicits their activation via a change in protein conformation, resulting dimerization with retinoid X receptor (RXR) and recruitment of co-activators like histone deacetylases (HDAC’s), p300/CBP or members of the steroid receptor co-activator (SRC) family (43, 44). This is followed by either direct binding to a consensus sequence on the DNA or to enable binding to other transcription factors like NF-kappaβ to regulate gene expression (45, 46).

To date, three isotypes of the receptor have been identified - PPAR α, β and γ. All three subtypes, possess the canonical domain structure common to other nuclear receptor family members: the amino-terminal AF-1 trans activation domain, followed by a DNA-binding domain, and a dimerization and ligand-binding domain with a ligand-dependent trans activation function AF-2 located at the carboxy-terminal region (47). Although, each subtype is a product of a distinct gene and they have organ specific expression pattern. PPAR’s and their functions in different systems have been widely studied. Briefly, PPARα is expressed primarily in brown adipose tissue, in liver, kidney, heart and skeletal muscle. It has been implicated in
mitochondrial fatty-acid (FA) oxidation, which provides energy for peripheral tissues (48). It’s involvement in antioxidant pathways is suggested to contribute to the pathogenesis of age-related macular degeneration (AMD) (48, 49). PPARβ is expressed predominantly in the gut, kidney and heart; and involved in lipid metabolism, cell survival, wound healing, embryonic implantation and development of the central nervous system (50). PPARγ is mainly expressed in adipose tissue and to a lesser extent in colon, the immune cells – macrophages and is known to be involved with processes such as adipogenesis and macrophage differentiation (51-53). The three PPAR’s also show expression in both male and female reproductive tissues. They are widely expressed in interstitial Leydig cells, Sertoli and germ cells, however their action in the testis is not completely clear (54, 55). In the female reproductive organs PPARα and PPARβ isoforms are expressed primarily in the theca and stroma tissues whereas PPARγ shows strong expression in the granulosa cells. Mice lacking PPARβ and γ are sub fertile suggesting an important role for these receptors in fertility (56).

Interestingly, all three subtypes show expression in the placenta also in the rodent placenta, they are expressed in the trophoblast cells of junctional zone as well as the labyrinth zone (57). They also show expression in the human placental trophoblast cells (57).

**Peroxisome proliferator-activated receptor-gamma (PPARγ)**

Regarding placental function and pregnancy, PPARγ has emerged as the crucial isoform owing to the embryonic lethality of the knockout mice due to gross placental abnormalities. While, the PPARα null mice show increased fetal loss (20% over wild type), surviving pups develop normally (58). PPARβ knockout mice also show an embryonic lethality due to defects placental morphogenesis, but some pups do survive (lethality >90%) (59, 60). PPARγ knockouts on the other hand show a 100% lethality rate due to defects in development of placental vasculature and thinning of the myocardial lining of the ventricles. Interestingly, correcting for
the mutation in these embryos (via aggregation with tetraploid embryos which contribute only to the extra-embryonic lineages) rescued the placental as well as the cardiac phenotype suggesting an important role for PPARγ in placental function. All three PPAR isotypes are expressed in the human trophoblast and a subset of endothelial cells (57). The role of the different molecules in human development though is only poorly understood. Aspects of PPARγ function in placental development have therefore been extensively explored in the human placenta. In the current chapter, we outline the current and potentially new roles of PPARγ in placental development and other functions at the maternal-fetal interface (Figure 3).

**Figure 3:** PPARγ has been shown to be involved in multiple key metabolic pathways in placentation and pregnancy. These include trophoblast differentiation, inflammatory and oxidative response and nutrient sensing - specifically fatty acid metabolism. Placental disorders such as PE often show changes in these pathways which are partially regulated by PPARγ. Changes in activity and not necessarily expression may result in altered fatty acid metabolism which in turn may influence villous and extra villous trophoblast differentiation. Similarly, altered activity may cause changes in oxidative stress and inflammation due to regulation and release of inflammatory cytokines such as TNF-α, IL-6 and others which have shown to be associated with conditions like pre-term labor, miscarriage and pre-eclampsia. The observation that all these factors are at least in part regulated by PPARγ supports its potential critical role in placental physiology and disease. (EVT: extra villous trophoblast, VT: villous trophoblast, HO-1: heme-oxygenase 1, NO: Nitric oxide)
**PPARγ in trophoblast differentiation**

Trophoblast differentiation is a critical process in establishment of placental lineages that govern the placental development, maintenance and function. We distinguish the human trophoblast cells into the decidua invading extra villous trophoblast (EVT) and the placenta residing villous trophoblast cells (VT) which are covered by the syncytiurn. EVT’s invade the maternal decidua to establish pregnancy and secure blood-flow to the implantation site which provides nutrients and oxygen to the fetus. The villous trophoblast forms the main maternal-fetal exchange surface, which is critical for fetal development and must adapt to environmental changes to secure growth throughout pregnancy. Trophoblast differentiation is a tightly regulated process in human-and is implicated to be abnormally regulated in placental dysfunction disorders (61-63). As mentioned previously, PPAR’s are expressed human trophoblast cells. However, while the expression of alpha and beta subtypes nuance as the cells differentiate, PPARγ continues to be expressed strongly in these cells (57, 64-67).

*In vitro* studies with 1st trimester EVT’s showed that treatment with PPARγ antagonists increased invasion whereas agonists hampered it, implicating involvement of PPARγ in regulating invasion of decidua (65). Similar study with isolated term villous trophoblast showed, induction of differentiation upon treatment with agonists (66). The VT has to balance cell proliferation and differentiation to sustain nutrient and gaseous exchange throughout pregnancy (68). Involvement of PPARγ in regulation of functions of both EVT’s and VT PPARγ not only suggest its crucial role in trophoblast differentiation but these studies also highlight the differences in response of the trophoblast subtypes to PPARγ induction.

Interestingly, the studies on term villous trophoblast also observed differential behavior of these cells in response to synthetic and naturally occurring ligands of PPARγ. Treatment with synthetic ligand - Troglitazone induced differentiation, whereas the natural ligand PGJ2 hindered
it, even inducing apoptosis in cells (66). Thus, PPARγ seems to have different roles depending upon 1) trophoblast subpopulations 2) the gestational age and type and 3) the stimulating ligand (69). However, one needs to bear in mind that isolated trophoblast lack their natural environment and tend to differentiate directly in culture which is a critical limitation in some of these studies (70, 71). Additionally, while we have substantial evidence for involvement of PPARγ in trophoblast differentiation, we still lack the understanding of the molecular regulation. Few studies focusing on downstream targets of PPARγ exist (72, 73). Glial cell missing 1 (Gcm-1) has emerged as an interesting candidate in this respect. It regulates differentiation of chorion into labyrinth trophoblast populations and controls syntiotrophoblast differentiation and mice lacking Gcm1 die at E10.5 due to absence of placental labyrinth (74). PPARγ deficiency in mouse trophoblast stem cells was shown to affect labyrinth cell lineages via Gcm-1 (75). Gcm1 has been shown to be also present in human trophoblast tissue and altered levels of Gcm-1 have been associated with PE placentas (76-78). Recently, Levystka K, et al showed that Gcm-1 levels could be altered by PPARγ agonists or antagonists in BeWo choriocarcinoma cells suggesting that PPARγ via Gcm-1 (79) may play a role in human trophoblast differentiation.

**PPARγ and Fatty Acid metabolism in the placenta**

Placental fatty acid (FA) transfer from the mother to the fetus is crucial for adequate development (80). PPARγ has been classically known for its role in lipid metabolism. The observation that the PPARγ knockout placentas showed less accumulation of lipid droplets suggested that it may have some similar function in the placenta. Schaiff T, et al in 2007 showed that PPARγ could alter the fatty acid uptake in the placenta by increasing the expression of fatty acid transport proteins (FTP’s) in mice (81).

Several fatty acid transporters (FABP, FATP and CD-36) have also been identified at the microvillous and basal membranes of the human placenta. Similar to observations in mice,
increase in PPARγ activity has been shown to increase fatty acid uptake and accumulation in primary human trophoblast cells by regulating the expression of proteins such as fatty acid binding proteins (FABP family) (71). In turn, oxidized LDL’s (low density lipoproteins) were shown to be capable of activating PPARγ in primary cytotrophoblast cells and even cause inhibition of trophoblast invasion (70, 82). Thus, PPARγ appears to be regulating and it self being regulated by lipid metabolites. PPARγ might act as a nutritional sensor and co-ordinate fatty acid uptake and trophoblast differentiation in the placenta to ensure growth and function. This helps to explain the placental insufficiency disorder phenotype such as PE which is associated by increased lipid peroxidation and defective trophoblast invasion (83, 84).

**PPARγ in placental oxidative stress**

Pregnancy is a state of physiological stress including oxidative stress. The initial hypoxia followed by reoxygenation (ischemic reperfusion) are the major contributors of oxidative stress during early pregnancy (85). In later stages, increased placental mitochondrial activity and production of reactive oxygen species (ROS) further contribute to the oxidative stress (8). In moderation, this normally does not cause a problem but excess oxidative stress has been observed in pregnancy complications like IUGR, diabetes and PE (8, 85, 86).

Nitric oxide (NO) is a vasodilator at normal levels, but at elevated levels it reacts with ROS to cause lipid peroxidation and nitrosylation of tyrosine residues affecting many signaling pathways. High levels of NO are also observed in GDM with cases shown to have higher levels of oxidative stress (87). Interestingly, blocking PPARγ greatly increases endogenous NO production suggesting that PPARγ might be involved in its regulation (8).

Heme oxygenase-1 (HO-1) is known for its anti-oxidant properties and cytoprotective effects. In the placenta, HO is found in vascular endothelium and villous and extra villous trophoblast (88). HO metabolites - carbon monoxide (a potent vasodilator) and bilirubin
negatively regulate endothelin 1 and ROS; and anti-angiogenic proteins such as soluble fms-like tyrosine kinase 1 (sFLT-1) (89, 90). Evidence showing regulation of HO-1 expression by PPARγ further emphasizes its potential role in managing oxidative stress and hypertension during pregnancy (91, 92).

**Immune mediated effects of PPARγ**

Pregnancy in general is a state dynamic inflammatory phases, wherein the immune status of the mother varies from being pro-inflammatory in the start of pregnancy, to anti-inflammatory in the middle phase to again being pro-inflammatory towards the end (93). There is also growing body of evidence suggesting that parturition at term is an inflammatory process with pro-inflammatory cytokines like IL-8 and TNF-α playing a role (94-96). Thus, a balance between the pro and anti-inflammatory modulators at the feto-maternal interface is crucial for maintenance of pregnancy. Indeed, a pre-mature (or untimely) shift towards the pro-inflammatory conditions has been associated with cases of spontaneous abortion and preterm delivery (97). Increased levels of pro-inflammatory cytokines like TNF-α, IL-6 and IL-8 have also been reported in PE cases (98, 99).

Interestingly, PPARγ has been known for its anti-inflammatory effects (100). It has also been shown to down regulate expression of pro-inflammatory cytokines like IL-6, IL-8, and TNF-α in human gestational tissue (101). Reduction in the levels of PPARγ during labor has also been documented (102). These observations together suggest that reduction in levels of PPARγ at term might contribute to parturition by regulating the expression of inflammatory cytokines. A premature reduction would thus ensure an inflammatory response which may result in loss of pregnancy.

**PPARγ expression levels and activity**

Studies assessing the protein levels of PPARγ associated aberrant levels of PPARγ with
placental disorders. Decreased levels of PPARγ were reported in cases of GDM, whereas increased levels were observed in IUGR associated PE (103, 104).

On the other hand, placentas from women with only PE did not show any changes in the levels of PPARγ protein expression (103, 104). These women showed significantly lowered levels of the activators (implicated to be a fatty acid derivative) of the receptor in their serum when compared to age matched controls (105). During a normal gestation, PPARγ activators increase as the pregnancy progresses to term (64). Women with PE showed a drop in these activating factors levels 10-15 weeks before presentation of symptoms (105). Lowered levels of the activators may lead to decreased activation of PPARγ which in turn may contribute to the pathology (105). While these studies emphasize the importance of PPARγ in placental pathologies, they also suggest that balance between the absolute levels of PPARγ protein and the level of activity is crucial.

Furthermore, Levystka et al. recently showed that that PPARγ underlies an auto-regulatory mechanism (79). The authors showed using the BeWo choriocarcinoma cell line that inhibition of PPARγ activity using an antagonist T0070907 led to an up-regulation of expression whereas activation by an agonist Rosiglitazone had the opposite effect. Thus, in-case of PPARγ increased levels of protein may not always correlate with increased activity. These factors need to be considered when investigating pathologic cases for the role of PPARγ. Studies on pathologic placentas, similar to those in cell lines will add on to our knowledge about molecular regulation of PPARγ in such pathologies.

**PPARγ as a therapeutic option in placental disorder**

Involvement of PPARγ with key aspects of pregnancy and the fact that it can be specifically modulated by a vast array of drugs already available makes it an attractive therapeutic option (30). McCarthy et al in 2011 showed that pregnant rats treated with synthetic
PPARγ antagonists developed pre-eclamptic phenotypes comparable to what has been described in human suggesting a relevant role in physiology and disease (106). More interestingly the same authors showed in a separate study that activation of the receptor by administration of its synthetic agonist Rosiglitazone, to the (reduced uterine perfusion pressure) RUPP rats showed considerable improvement in hypertension with no adverse effects on the litters or placental vasculature (30, 106). The RUPP model of rats resembles in parts the human PE condition, and administration of Rosiglitazone significantly reduced hypertension and improved vascular function in a HO-1 dependent manner (106). The authors did not observe any adverse effects on placental morphology which contrasts with some other studies (81, 107). The group argued that the low dosage used in the study and the time of administration of the drug contributed to the contrasting results. The study demonstrates the ease and effectiveness of PPARγ modulation using drugs with so far no observed side-effects, albeit in an animal model.

These parameters of low dosage and exposure times to the drugs seem to hold true in human cases too. A few human case reports assessed the effects of use of synthetic PPARγ agonists (Rosiglitazone and Pioglitazone) during pregnancy, although the drugs were shown to cross the maternal- fetal barrier but no harm to the fetus or induction of PE was noted (108-110). The dosage in these studies was not as high (dose 4 mg) as recommended for diabetic patients (8mg) and the duration of treatment was between 7 – 17 weeks of pregnancy. Additionally, while these drugs were previously thought to increase the risk of cardiovascular diseases in humans, recent reports do not support these claims and the drugs have been recently approved by the FDA for widespread use (111).

While further studies and risk assessment would be necessary to ensure safety, PPARγ is a strong candidate for development of therapies managing pregnancy related disorders. This dissertation project explores the role of PPARγ in placental development and pregnancy per the
following aims:

Aim 1: To determine the molecular mechanism of PPARγ in prevention of preterm birth in the mouse model for endotoxin induced PTB. (Outlined in Chapter 2 & 3)

Aim 2: To determine the effects of endotoxin exposure and PPARγ induction on human trophoblast physiology. (Outlined in Chapter 4)

Aim 3: To determine the role of PPARγ in differentiation of extra-villous and villous trophoblast lineages. (Outlined in Chapter 5 & 6)
CHAPTER 2 - PPARγ PREVENTS INFLAMMATION INDUCED PRETERM BIRTH BY ATTENUATING BOTH SYSTEMIC AND LOCAL INFLAMMATORY PATHWAYS

(This chapter contains previously published material. See Appendix D)

Introduction

Preterm birth (PTB), defined as delivery before 37 weeks of gestation, is the leading cause of neonatal morbidity and mortality (112-114). Premature neonates are at high risk of short-term complications such as respiratory distress syndrome, inter-ventricular hemorrhage, neonatal sepsis, and necrotizing enterocolitis. Long-term complications include neuro-developmental disorders such as cerebral palsy, chronic lung disease, blindness, and deafness (115-117). In the United States, preterm births accounted for 11.39% of all documented births in 2013 (118). Therefore, it is critical to elucidate the mechanisms that lead to preterm labor (PTL) to provide strategies for the prevention of PTB and the improvement of neonatal outcomes.

PTL is a syndrome caused by multiple pathological processes (119). Of all the potential causes, intra-amniotic infection/inflammation is the only direct link to PTL that accounts for about 30% of all PTBs (120-122). Infection results in a transition from an anti-inflammatory to a pro-inflammatory physiological state in the mother. This involves the infiltration of innate immune cells, such as macrophages, and an increased expression of inflammatory mediators at the uterine-placental unit. Activation of this pro-inflammatory response triggers PTL and consequently PTB (121, 123-125).

In order to study the mechanisms of inflammation-induced PTL, animal models have been developed using mice (126-129), rats (130, 131), rabbits (132), sheep (133), guinea pigs (134, 135) and monkeys (136, 137). The most common model is the murine model, in which PTL can be induced by the systemic administration of bacterial lipopolysaccharides (LPS) (138). LPS administration to pregnant mice triggers an inflammatory response, activating key signal
transduction pathways such as NF-κB and TNF-α that ultimately will lead to PTB (139, 140). These pathways are similarly activated in inflammation-induced PTL in humans (141).

The ligand-activated transcription factor PPARγ while mostly known for its role in lipid metabolism and insulin sensitivity has a proven anti-inflammatory role (142-146). Upon activation, PPARγ has been shown to suppress the transcription of inflammatory signal transduction pathways, such as NF-κB and TNF-α (100, 147). The anti-inflammatory role of PPARγ has also been recognized in diseases like multiple sclerosis (MS) and atherosclerosis (148, 149). However, its potential role in inflammation induced PTB remains unexplored. Our group recently showed in a human trophoblast cell line (150), and in a rat model of PE, that PPARγ activation via Rosiglitazone induced HO-1 expression, improved vascular function and pregnancy outcomes (30, 106). PPARγ has also been implicated in human parturition and dramatically reduced levels were reported during labor as compared to early gestation (102). Activation of PPARγ was also shown to reduce expression of inflammatory cytokines from human gestational tissues (101, 151). These observations suggest that reduced PPARγ activity might regulate the onset of parturition by suppressing inflammatory cytokines. Further, availability of approved drugs like Rosiglitazone that can specifically target PPARγ make it an attractive target for therapeutic interventions.

In the current study, we aimed to study the potential anti-inflammatory role of PPARγ in inflammation induced PTB. Using the LPS induced preterm birth model in mice, and Rosiglitazone to modulate PPARγ activity we aimed to: (i) determine whether treatment with RSG reduces the rate of LPS-induced preterm birth and improves neonatal outcomes; (ii) evaluate whether treatment with RSG reduces the systemic proinflammatory response in pregnant mice injected with LPS.
Recently, St Louis D et al. demonstrated that PPARγ activation reduces the expression of inflammatory genes in activated uterine macrophages in a model of PTB induced by iNKT-cell activation (152). Given that during pregnancy local inflammatory cytokines are mostly produced by innate immune cells such as macrophages and neutrophils (153, 154), and the depletion of macrophages, but not neutrophils, prevents inflammation-induced PTB (155, 156) we also evaluated if PPARγ activation has a direct effect on macrophages at the uterine-placental unit.

Materials and Methods

Animal treatments

C57BL/6J mice were bred in the animal care facility at the C.S. Mott Center for Human Growth and Development at Wayne State University, Detroit, Michigan, USA, and housed under a circadian cycle (light: dark=12:12 h). Females 8-12 weeks old were mated with male mice of proven fertility. Female mice were examined daily between 8:00 a.m. and 9:00 a.m. for the presence of a vaginal plug, which denoted 0.5 days post coitum (dpc). Upon observation of vaginal plugs, female mice were then separated from the males and housed in different cages. Procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at Wayne State University (Protocol No. A09-08-12).

Pregnant mice were categorized into four different groups and injected intraperitoneally on 16.5 dpc with: 1) 10μg of LPS (Escherichia coli O111:B4; Sigma-Aldrich, MO) in 200 μL of 1X PBS (n=10); 2) 200μL of PBS as a control; 3) 10μg of LPS in 200μL of 1X PBS followed by 10mg/kg RSG 6 hours after the initial injection (n=10); and 4) 10mg/kg of RSG as a control (Figure 2A). RSG was dissolved in 1:10 DMSO; therefore, pregnant mice were also intraperitoneally injected on 16.5 dpc with 1:10 DMSO as a control (n=6). Pregnancy parameters including gestational age and the rates of preterm birth and stillbirth were recorded.
via video camera (Sony Corporation, China). Preterm birth was defined as delivery before 18 dpc, and its rate was defined as the percentage of dams delivering preterm among all births. The stillbirth rate was defined as the percentage of pups born dead out of the total litter size. All DMSO control mice delivered at term (19.5 ± 0.5 dpc); therefore, the gestational age is shown instead of the rate of preterm birth. Gestational age was calculated from the presence of the vaginal plug (0.5 dpc) until the observation of the first pup born.

Figure 4: Rosiglitazone treatment reduces the rate of LPS-induced PTB and improves neonatal outcomes. A) On 16.5 dpc, pregnant mice were i.p. injected with LPS and treated 6 hours after with rosiglitazone (RSG; i.p.) and video-monitored. Control mice were injected with LPS, PBS, or RSG alone. (B) The rate of PTB was defined as the percentage of dams delivering at <18.0 dpc among all births. (C) The rate of stillbirth for each litter was defined as the proportion of born pups found dead out of the total litter size. Data are shown as bar plots (mean ± SEM). Mann-Whitney U tests: n = 10 each. Fetal weights (D) and placental weights (E) two hours following PBS, LPS, LPS+RSG, or RSG injection. Data are shown as scatter plots (median). T-tests: n = 8 dams each.
**Fetal and placenta weights**

A second cohort of pregnant mice was injected intraperitoneally on 16.5 dpc with LPS, PBS, LPS + RSG or RSG (n=8 each), as described previously. Two hours after injection, mice were euthanized, and peripheral blood was collected by cardiac puncture and placed into a 1.5 safe-lock Eppendorf tube (Fisher Scientific, MA) (Figure 4A). Animal dissection and tissue collection (myometrial and decidual tissues) were performed as previously described (125). The pup and placental weights were determined using a weight scale (DIA-20, American Weight Scales, GA).

**Chemokine/cytokine serum concentrations**

Peripheral blood samples were centrifuged at 491 x g for 10 min at 4°C, and serum was separated and stored at -20°C until analysis. The Milliplex MAP Mouse Cytokine/Chemokine Kit (MCYTOMAG-70K-PX32, EMD Millipore, MA) was used to measure the concentrations of G-CSF, GM-CSF, IFNγ, IL1α, IL1β, IL2, IL3, IL4, IL5, IL6, IL7, IL9, IL10, IL12p40, IL12p70, IL13, IL15, IL17, CCL11, CXCL10, CXCL1, LIF, CXCL5, CCL2, M-CSF, CXCL9, CCL3, CCL4, CXCL2, CCL5, and TNFα in the serum samples, per the manufacturer’s instructions. Plates were read using the Luminex 100 System (Luminex Corporation, TX), and analyte concentrations were calculated using the xPONENT3.1 software (Luminex). The sensitivities of the assays were: 1.7pg/ml (G-CSF), 1.9pg/ml (GM-CSF), 1.1pg/ml (IFNγ), 10.3pg/ml (IL1α), 5.4pg/ml (IL1β), 1.0pg/ml (IL2), 1.0pg/ml (IL3), 0.4pg/ml (IL4), 1.0pg/ml (IL5), 1.1pg/ml (IL6), 1.4pg/ml (IL7), 17.3pg/ml (IL9), 2.0pg/ml (IL10), 3.9pg/ml (IL12p40), 4.8pg/ml (IL12p70), 7.8pg/ml (IL13), 7.4pg/ml (IL15), 0.5pg/ml (IL17), 1.8pg/ml (CCL11), 0.8pg/ml (CXCL10), 2.3pg/ml (CXCL1), 1.0pg/ml (LIF), 22.1pg/ml (CXCL5), 6.7pg/ml (CCL2), 3.5pg/ml (M-CSF), 2.4pg/ml (CXCL9), 7.7pg/ml (CCL3), 11.9pg/ml (CCL4), 30.6pg/ml (CXCL2), 2.7pg/ml
(CCL5), and 2.3pg/ml (TNF-α). Inter-assay and intra-assay coefficients of variation were below 15% and 4.9%, respectively.

**Macrophage isolation from murine myometrial and decidual tissues**

Immediately after collection, myometrial and decidual tissues were mechanically disaggregated in the Accutase cell dissociation reagent (Life Technologies, CA) using scissors for approximately 1-2 min, as previously described (125). Samples were then incubated at 37°C for 35 min with gentle shaking (MaxQ™ 4450 Benchtop Orbital Shaker, Thermo Fisher Scientific, MA). The cell suspensions were filtered using a 100μm cell strainer (Fisher Scientific, MA) and washed with staining buffer [Bovine-serum albumin 0.1% (Sigma Aldrich, MO), sodium azide 0.05% (Fisher Scientific Bioreagents, MA), 1X PBS (Fisher Scientific Bioreagents). The resulting cell pellet was re-suspended in 96μl of staining buffer, and 4μl of an anti-mouse F4/80 antigen biotin (clone BM8, eBioscience) were added. The cell suspension was then incubated for 15 min at 4°C. After incubation, the cells were washed with 2 ml of staining buffer and centrifuged at 1250 x g for 7 min at 4°C. The cell pellet was re-suspended in 90 μl of staining buffer, and 10μl of Streptavidin microbeads (Miltenyi Biotec, Germany) were added. This cell suspension was incubated at 4°C for 15 min. Following incubation, the cells were washed with 2 ml of staining buffer, and the cell pellet was re-suspended in 500 μL of MACS buffer. F4/80⁺ cells (macrophages) were separated by positive selection using MS columns and a magnetic MACS separator. Macrophages were then washed with MACS buffer at 1250 x g for 7 min at 4°C, and an aliquot was taken to confirm purity by flow cytometry using an anti-mouse F4/80-PE (Clone BM8, eBioscience; Figure 6A). The cell pellet was re-suspended in 400μL of RNeasy Lysis Buffer (Qiagen, Germany) and placed into a 1.5mL safe-lock Eppendorf tube (Fisher Scientific, MA), which was stored at -80°C until RNA isolation.
RNA isolation, cDNA synthesis, and qRT-PCR

Total RNA was isolated from myometrial and decidual macrophages using the RNeasy mini kit (Qiagen, Germany), following the manufacturer’s instructions. RNA concentrations and purity were assessed with the NanoDrop 1000 spectrophotometer (Thermo Scientific, MA), and RNA integrity was evaluated with the 2100 Bioanalyzer system (Agilent Technologies, CA) using the Agilent RNA 6000 Pico Kit (Agilent). cDNA was synthesized by using iScript Reverse Transcription Supermix for RT-qPCR kits (Bio-Rad Laboratories, CA) on the Applied Biosystems GeneAmp PCR System 9700 (Life Technologies, MA), following the manufacturer’s instructions. cDNA was amplified using the SsoAdvanced PreAmp Supermix (Bio-Rad Laboratories, CA) on the Applied Biosystems GeneAmp PCR System 9700. mRNA expression of \textit{Nfkb1}, \textit{Tnf}, and \textit{Il10}, and housekeeping genes (\textit{Actin}, \textit{Gapdh}, and \textit{Tbp}) was determined by qPCR using the LuminoCtÔ SYBR Green qPCR ReadyMix (Sigma Aldrich, MO) on the CFX384 Touch Real-Time PCR Detection System (Bio-Rad Laboratories, CA), per the manufacturer’s instructions. Primers are described in Table 1.

\textbf{Table 1: List of primers sequences used for gene expression analysis in mouse decidual and myometrial macrophages}

<table>
<thead>
<tr>
<th>Gene Name</th>
<th>Gene Symbol</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glyceraldehyde 3-phosphate dehydrogenase</td>
<td>Gapdh</td>
<td>5'-AAT GGT GAA GGT CCG TGT G-3'</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5'-GTG GAG TCA TAC TGG AAC ATG TAG-3'</td>
</tr>
<tr>
<td>\textit{ß}-actin</td>
<td>\textit{Actin}</td>
<td>5'-GCG AGC ACA GCT TCT TTG-3'</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5'-ATG CCG GAG CCG TTG TC-3'</td>
</tr>
<tr>
<td>TATA Box Binding Protein</td>
<td>\textit{Tbp}</td>
<td>5'-TTC ACC AAT GAC TCC TAT GAC C-3'</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5'-CAA GGT TAC AGC CAA GAT TCA CG-3'</td>
</tr>
<tr>
<td>Interleukin-10</td>
<td>\textit{Il-10}</td>
<td>5'-TCA GCC AGG TGA AGA CTT TC-3'</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5'-GGC ACT TCT ACC AGG TAA-3'</td>
</tr>
<tr>
<td>Tumor Necrosis Factor-\textit{α}</td>
<td>\textit{TNF-α}</td>
<td>5'-AGA CCC TCA CAC TCA GAT CA-3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5'-TCT TGT AGA TCC ATG CCG TTG TG-3'</td>
</tr>
<tr>
<td>Nuclear Factor of \textit{κ} Light Polypeptide Gene Enhancer in B-Cells 1</td>
<td>\textit{NF-kb}</td>
<td>5'-AGT CAC ATC TGG TTT GAT CTC TG-3'</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5'-CCT CTA CTA CAT CTT CCT GCT TG-3'</td>
</tr>
</tbody>
</table>
**Immunofluorescence**

Myometrial and decidual tissues from mice injected with LPS, PBS, LPS + RSG, or RSG (n = 5 each) were immediately frozen in Tissue-Tek O.C.T Compound (Sakura Finetek, CA). Ten-micrometer-thick cryosections were cut and placed on Fisherbrand Superfrost Plus microscope slides (Thermo Scientific, MA). After fixation with 4% paraformaldehyde (Electron Microscopy Sciences, PA), the slides were washed with 13 PBS containing 0.1% Tween 20 and permeabilized with 13 PBS containing 0.25% Triton X-100 for 10 min. Nonspecific Ab interaction was blocked using serum (KPL, MD) at room temperature for 1 h. Slides were then incubated with the following rabbit anti-mouse Abs: 10 mg/ml IL-10 (Abcam, UK), 33 mg/ml TNF, or 2 mg/ml NF-κB1 (Novus Biologicals, CO) at 4°C overnight. After washing with PBS containing 0.1% Tween 20, the slides were incubated with 2 mg/ml goat anti-rabbit secondary Ab conjugated to Alexa Fluor 594 (Invitrogen Molecular Probes, MA) at room temperature for 1 h, washed again with 13 PBS containing 0.1% Tween 20, and incubated with 2 mg/ml rat anti-mouse F4/80 Ab directly conjugated to FITC (Abcam, UK) at room temperature for 2 h. After mounting with ProLong diamond antifade mountant with DAPI (Life Technologies, CA), immunofluorescence was visualized using an Olympus BX 60 fluorescence microscope (Olympus, Japan) at 1000x original magnification. The pictures were taken using an Olympus DP71 camera and DP Controller Software (Olympus, Japan). The images were merged using ImageJ 1.44p.

**Statistical analysis**

The qRT-PCR data analysis was performed in R (http://www.R-project.org/), and for all other data analyses, IBM SPSS Version 19.0 (IBM Corporation, NY) was used. For qRT-PCR data analysis, the statistical significance of group comparisons was assessed using the Mann-
Whitney U test. For qRT-PCR data, negative ΔCt values were determined using two reference genes (Gapdh and Actb or Tbp) averaged within each sample to determine gene expression levels. For the rate of stillbirth, the statistical significance of group comparisons was assessed using the Mann-Whitney U test. For fetal and placental weights, the statistical significance of group comparisons was assessed using T-tests. For cytokine concentrations, multiple comparisons were performed using analysis of variance and the Sidak post-hoc tests. For human demographic data, the statistical significance of group comparisons was performed using the Chi-square test for proportions as well as the Kruskal-Wallis test for non-normally distributed continuous variables. A p-value < 0.05 was used to determine statistical significance.

Results

**Rosiglitazone treatment reduced the rate of LPS-induced preterm birth and stillbirth**

To study the in vivo effect of PPARγ activation on preterm birth, we determined whether administration of RSG could rescue LPS-induced preterm birth (Figure 4A). As expected, LPS injection induced 80% of preterm births (128) (Figure 4B). When pregnant mice were injected with LPS followed by treatment with RSG, a 30% reduction in the rate of preterm birth was observed (LPS versus LPS + RSG; Figure 4B). No preterm births were observed in mice injected with PBS or RSG alone (Figure 4B). The rate of pup mortality in mice injected with LPS was 100% (Figure 4C) yet, this was reduced by 41% after the treatment with RSG (LPS versus LPS + RSG; Figure 4C). Because RSG was dissolved in DMSO, it was essential to investigate whether DMSO alone had adverse effects in pregnancy. All mice injected with DMSO delivered at term, as in mice injected with PBS (19.5± 0.5 d; Figure 4D). Also, mice injected with DMSO had a low rate of pup mortality, similar to those injected with PBS (8–13%; Figure 4E). Next, we examined the effects of RSG treatment on fetal and placental weights. LPS
injection reduced fetal weight (LPS versus PBS; Figure 4F), but body mass was restored following treatment with RSG (LPS+RSG versus LPS; Figure 4F). The reduced placental weight (LPS versus PBS; Figure 4G), and this was not restored by treatment with RSG (LPS + RSG versus RSG; Figure 4G). The administration of RSG alone did not alter placental weight (RSG versus PBS; Figure 4G). These data demonstrate that treating mice with RSG reduces the rate of LPS-induced preterm birth, as well as improves adverse neonatal outcomes.

*Rosiglitazone treatment attenuated the systemic pro-inflammatory response induced by LPS*

Preterm labor/birth is associated with a systemic pro-inflammatory response (122, 124, 125, 157-165). Therefore, we determined whether treatment with RSG reduced the elevated systemic concentrations of cytokines/chemokines induced by LPS. As expected, LPS increased the systemic concentration of several cytokines and chemokines when compared with the PBS control group (LPS vs. PBS; Figure 5A-C). Treatment with RSG attenuated the LPS-induced pro-inflammatory response by reducing the concentrations of several cytokines and chemokines including TNFα, IL1β, IL3, IL4, IL9, IL10, IL12 (p40 and p70), IL13, IL15, GM-CSF, CCL2, CCL3, CCL4, CXCL2, CXCL5, and CXCL10 (LPS+RSG vs. LPS, Figure 3A & 3B). In addition, treatment with RSG increased the systemic concentrations of IL5 and CXCL9 in mice injected with LPS (LPS+RSG vs. LPS, Figure 5A and B). However, treatment with RSG did not reduce the systemic concentration of LPS-induced IFNγ, IL1α, IL2, IL6, LIF, G-CSF, M-CSF, CCL5, and CCL11 (, Figure 3C). The administration of RSG alone did not alter the basal concentrations of cytokines/chemokines (RSG vs. PBS, Figure 5A-C).
These results demonstrate that treatment with RSG attenuates the LPS-induced pro-inflammatory response in the mother, which provides insight into the systemic immune mechanisms whereby this PPARγ agonist prevents LPS-induced PTB.

Figure 5: Rosiglitazone treatment attenuates the systemic inflammatory response induced by LPS. A) Serum concentrations of cytokines in mice injected with PBS, LPS, LPS + rosiglitazone (RSG), and RSG alone. B) Serum concentrations of chemokines in mice injected with PBS, LPS, LPS + RSG, and RSG alone. Data are shown as bar plots (mean ± SEM). Sidak T-tests: n = 8 each. *p ≤ 0.05 LPS vs. PBS; "p ≤ 0.05 LPS+RSG vs. PBS; "p ≤ 0.05 LPS vs. LPS + RSG.
Rosiglitazone treatment attenuated LPS induced macrophage activation in myometrial and decidual macrophages

PPAR\(\gamma\) activation suppresses gene transcription by interfering with signal transduction pathways, such as the NF-\(\kappa\)B, STAT, and AP-1 pathways (166-168), and induces an M2 macrophage polarization (169). Therefore, we investigated whether PPAR\(\gamma\) activation in vivo through treatment with RSG alters the NF-\(\kappa\)B pathway, and the expression of M1 and M2 cytokines in decidual and myometrial macrophages from pregnant mice injected with LPS (Figure 6A). Decidual and myometrial macrophages (F4/80\(^+\) cells) were isolated, and their purity was confirmed by flow cytometry (88%-97%; Figure 6A). mRNA expression of \(Nfkb1\) (a pathway regulated by PPAR\(\gamma\) activation (166)), \(Tnf\) (an M1 cytokine (170)), and \(Il10\) (an M2 cytokine (170)) were determined in isolated macrophages. LPS injection up-regulated the expression of \(Nfkb1\), \(Tnf\), and \(Il10\) in decidual and myometrial macrophages (LPS vs. PBS; Figure 6B-6G); however, the mRNA abundance of these genes was down-regulated upon treatment with RSG (LPS+RSG vs. LPS; Figure 6B-G). In decidual macrophages, the LPS-induced expression of \(IL10\) was partially reduced upon treatment with RSG (LPS+RSG vs. LPS; Figure 6D). The administration of RSG alone did not alter the expression of any of these genes (RSG vs. PBS; Figure 6B-6G). These results demonstrate that treatment with RSG down-regulates the LPS-induced expression of \(Nfkb1\), \(Tnf\), and \(Il10\) in decidual and myometrial macrophages, which provides insight into the local immune mechanisms whereby this PPAR\(\gamma\) agonist prevents LPS-induced PTB.

The protein expression of NF-\(\kappa\)B, TNF, and IL-10 was also determined via immunofluorescence in myometrial and decidual macrophages. Consistent with our mRNA data, LPS-induced expression of NF-\(\kappa\)B, TNF, and IL-10 in myometrial macrophages was reduced upon treatment with RSG (Figure 7A-C). Similar results were found in decidual
macrophages (data not shown).

Figure 6: Rosiglitazone treatment reduces the mRNA expression of Nfκb1, Tnf, and Il10 in decidual and myometrial macrophages. A) On 16.5 dpc, pregnant mice were i.p. injected with LPS and treated 6 hours after with rosiglitazone (RSG; i.p.), and two hours after decidual and myometrial macrophages were isolated by magnetic cell sorting. Control mice were injected with LPS, PBS, or RSG alone. Macrophage purity (F4/80+ cells, >85%) was determined by flow cytometry. The gray histogram represents the auto fluorescence signal from an unstained sample, and the purple histogram represents the fluorescence signal from a stained sample. B & E) NfκB1 mRNA expression by isolated decidual or myometrial macrophages. C & F) Tnf mRNA expression by isolated decidual or myometrial macrophages. D & G) Il10 mRNA expression by isolated decidual or myometrial macrophages. Data are shown as scatter plots (median). Mann-Whitney U tests: n = 5-7 each.
Figure 7: RSG treatment altered the protein expression of NF-κB, TNF, and IL-10 in myometrial macrophages. On 16.5 dpc, pregnant mice were injected with LPS and treated with RSG 6 h after. Two hours after injection, myometrial tissues were processed for histology. Control mice were injected with LPS, PBS, or RSG alone. NF-κB (A, red signal), TNF (B, red signal), and IL-10 (C, red signal) expression in myometrial macrophages (F4/80+ cells, green signal) was determined by immunofluorescence. Nuclei are blue (DAPI). Original magnification = 31000. n=5 each.

Discussion

In the current study, we evaluated if activation of PPARγ could rescue inflammation-induced PTB. PPARγ is a hormone nuclear receptor (40, 171) that binds lipid metabolites including eicosanoids, polyunsaturated fatty acids, and oxidized phospholipids as well as synthetic thiazolidinedione’s (e.g., RSG and GW1929) (172). PPARγ is expressed in the fetal membranes and placenta (173, 174) as well as in the reproductive tissues (175-177). PPARγ has
an essential role in placental development as its depletion interferes with terminal differentiation of the trophoblast and placental vascularization, causing fetal death (178). In later stages of gestation, the PPARγ pathway is linked to the inflammatory process of parturition in both term and preterm stages (101, 151, 174, 177, 179-183). Defective PPARγ signaling is associated with pregnancy complications (184, 185) including GDM (186), IUGR (187, 188), PE (30, 105, 189, 190), and preterm birth (182, 191). Conversely, PPARγ activation via 15-deoxy-Δ₁₂,₁₄-Prostaglandin J₂ delays LPS-induced PTB and reduces neonatal mortality by promoting the resolution of inflammation (192). However, the administration of 15-deoxy-Δ₁₂,₁₄-Prostaglandin J₂ alone has negative effects on gestational length, causing late PTB (192). In this study, PPARγ activation via RSG reduced the rates of LPS-induced PTB by 30% (Figure 4B) and stillbirth by 40% (Figure 4C) Further, the administration of RSG alone did not have adverse effects on the mother or offspring (Figure 4E).

To assess the effects of RSG administration on systemic inflammatory process, we analyzed the levels of pro and anti-inflammatory cytokines and chemokines in sera from mice LPS and LPS + RSG group. Administration of LPS induced and inflammatory response in the mice and we observed a significant increase in serum levels of pro-inflammatory cytokines (Figure 5A-C). The systemic inhibitory activity of RSG on inflammatory cytokines has been previously demonstrated in non-pregnant mice (193-195) and rats (196, 197) injected with inflammatory stimuli, as well as in patients with diabetic and nondiabetic coronary artery disease (198) or obesity (199). Similar to the observations in these reports, administration of RSG significantly reduced the expression of pro-inflammatory cytokines in our model (Figure 5A-C). These results demonstrated that PPARγ mediated reduction in PTB acts via attenuation of the systemic inflammatory response. Interestingly, in our study we observed that treatment with
RSG increased the serum concentration of LPS-induced IL5 and CXCL9. IL5 is a Th2 cytokine that is implicated in eosinophilic responses and B-cell proliferation (200), and CXCL9 is involved in T-cell trafficking (201) in chronic inflammatory processes (202, 203). Previous reports, however, have demonstrated that treatment with RSG reduces bronchoalveolar lavage fluid or serum concentrations of IL5 in rodent models of asthma (204, 205) and attenuates tissue eosinophilia induced by this cytokine (206). In the same fashion, treatment with RSG inhibits the release of CXCL9 induced by the IFNs (α,γ,β) in primary cultures of human thyroid follicular cells (207) and by IFNγ and TNFα in primary cultures of thyrocytes, retrobulbar fibroblasts, and retrobulbar preadipocytes obtained from Graves' ophthalmopathy patients (208). These disparities may be due to our study being performed in pregnant mice, and the serum sampling conducted shortly after LPS injection. However, further research is needed to investigate whether increased serum concentrations of IL5 and CXCL9 contribute to the effectiveness of RSG in preventing LPS-induced PTB.

In addition to reproductive organs, PPARγ is expressed by adipose tissue and immune cells (54) including monocytes/macrophages (100, 166, 167, 209). Activation of PPARγ has been shown to induce an anti-inflammatory profile in macrophages, which is impaired in macrophage-specific PPARγ knockout mice, suggesting a critical role for PPARγ in macrophage anti-inflammatory responses (210). Interestingly, LPS induced PTB is completely abrogated in pregnant mice with depleted macrophages, suggesting these are the crucial cell type propagating the effects of LPS(155). To understand the mechanism for RSG mediated PTB prevention, we decided to study the inflammatory gene expression in macrophages isolated for animals in the LPS and LPS + RSG treated animals. Since PTB is characterized by infiltration of macrophages at the maternal fetal unit, macrophages for the current study were isolated from these tissues.
Treatment with RSG significantly reduced the expression of *Nfkb1*, *Tnf*, and *Il10* by myometrial and decidual macrophages from mice injected with LPS (Figure 6B-G). The suppressive role of PPARγ activation in macrophages has been previously demonstrated in the NF-κB pathway (166, 167, 211), and in the expression/secretion of TNFα (100, 211-213) and IL10 (214, 215). Similarly, in our study the macrophages from the LPS + RSG group had significantly lower expression of *Nfkb1*, *Tnf*, and *Il10*. These changes in mRNA expression level were also reflected at the protein level (Figure 7A-C). Taken together, these data demonstrate that RSG prevents LPS-induced PTB by suppressing the local pro-inflammatory response mediated, at least in part, by decidual and myometrial macrophages.

In summary, the study herein demonstrates that PPARγ activation via RSG can attenuate the LPS-induced systemic and local pro-inflammatory responses mediated by macrophages, preventing PTB and improving neonatal outcomes. These findings suggest that the PPARγ pathway is a new molecular target for future preventative strategies for spontaneous preterm labor/birth.
CHAPTER 3 - ROSIGLITAZONE REGULATES TLR4 AND RESCUES HO-1 AND NRF2 EXPRESSION IN MYOMETRIAL AND DECIDUAL MACROPHAGES INFLAMMATION-INDUCED PRETERM BIRTH

(This chapter contains previously published material. See Appendix E)

Introduction

Preterm birth (PTB) is defined as delivery before 37 weeks of gestation and affects approximately 9.62% of births in 2015 (37). Premature neonates are at risk for short and long term health problems; making PTB one of the leading causes of neonatal mortality and morbidity worldwide (216). Approximately 70% of all PTBs are preceded by spontaneous preterm labor (PTL) (120, 217-220), a syndrome of multiple pathological processes (119). Of all the putative causes associated with spontaneous preterm labor, only intra-amniotic infection/inflammation has been causally linked to PTB (221-223). Inflammation-associated PTB is characterized by increased expression of pro-inflammatory proteins and infiltration of immune cells in the maternal-fetal interface (154), as well as elevated oxidative stress (122, 123, 224). Several animal models have been established to study the mechanisms whereby inflammation induces PTB (126, 130, 132). Lipopolysaccharide (LPS)-induced PTB is the most widely used model (138). In pregnant mice, administration of LPS induces an inflammatory response resulting in premature delivery (225). LPS binds to Toll-like receptor-4 (TLR4), which recruits the adaptor protein myeloid differentiation factor 88 (Myd88) (226) in order to initiate the activation of pro-inflammatory proteins such as the transcription factor - Nf-κB (227, 228). Activation of the Nf-κB pathway results in the expression of inflammatory cytokines such as TNF-α and IL-1β(226), triggering an inflammatory cascade that ultimately leads to PTL and PTB. Like the human syndrome, LPS-induced PTB increases oxidative stress and promotes the infiltration of neutrophils and macrophages at the maternal-fetal interface (124, 229-231). Therefore, targeting pro-inflammatory macrophages at the maternal-fetal interface may represent a new strategy to
prevent inflammation-associated PTB.

Pro-inflammatory macrophages are present at the maternal-fetal interface in term (i.e. physiological inflammation) and preterm (i.e. pathological inflammation) parturition (154, 232-234). Such innate immunity cells have a pro-inflammatory or M1-like phenotype in both processes of labor, which can be attenuated by administering Rosiglitazone (Rosi) (235). Rosiglitazone belongs to the thiolidazone family of compounds and acts as a specific agonist for the nuclear hormone receptor, Peroxisome proliferator activated receptor-gamma (PPARγ) (235). PPARγ is known for its role in lipid metabolism, adipocyte differentiation as well as for regulating the genes involved in inflammation and oxidative stress (52, 142, 236, 237). Interestingly, PPARγ knockouts die in-utero due to placental abnormalities suggesting a pivotal role in placentation (178). Altered levels of PPARγ levels or its activators have been associated with pregnancy-related pathologies such as GDM, IUGR and pre-eclampsia (103-105); however, its potential role in preterm birth remained unexplored. Recently, we showed that treatment with Rosiglitazone 1) reduced the rate of LPS-induced preterm birth by 30%, 2) reduced the rate of stillbirth by 41%, and 3) significantly downregulated the systemic inflammatory response in mice (235). Therefore, by targeting the PPARγ pathway we could reduce the inflammatory effects of LPS.

In addition to inflammation, elevated oxidative stress is a major contributor to LPS-induced preterm birth (224, 238). Indeed, anti-oxidant supplementation has been demonstrated to improve pregnancy outcomes in different models of preterm birth (230, 231, 239). We therefore aimed to evaluate whether Rosiglitazone had similar actions in our model of preterm birth. In the study herein, we focused on Nuclear factor (erythroid-derived 2)-like 2 (NRF2) and its downstream target Heme oxygenase-1 (HO-1) due to their dual role as anti-inflammatory and
anti-oxidative regulators (240, 241). NRF2 is a transcription factor that regulates the expression of proteins involved in the detoxification of oxygen radicals by binding to anti-oxidant response element (ARE) in gene promoters (242). Additionally, it has been reported to block inflammatory signaling in bone marrow derived macrophages and reduce inflammation in a thrombin induced PTB model (243, 244). HO-1, is the rate limiting enzyme catalyzing the breakdown of heme, producing carbon monoxide and biliverdin. Biliverdin is then degraded further into bilirubin which is a strong anti-oxidant (245). HO-1 has been shown to play a critical role in placental function and reduced levels have been associated with pre-eclampsia and cases of spontaneous abortions (246, 247). HO-1 has also been shown to reduce myometrial contractility and may thus play a role in PTB (248).

Rosiglitazone has been shown to upregulate the expression of both NRF2 and HO-1 in hepatocytes (249), but its effects on expression in decidual and myometrial macrophages is unknown. Herein, we hypothesized that treatment with Rosiglitazone would improve pregnancy outcomes in an LPS-induced model of preterm birth by indirectly affecting the inflammatory cascade by regulating TLR4 receptor and reducing oxidative stress by upregulating the anti-oxidant factors NRF2 and HO-1.

**Materials and Methods**

**Animal treatments**

Pregnant C57BL/6J mice were divided into 4 groups and received intraperitoneal injections on 16.5 dpc: Group I: LPS – received 10μg of LPS (*Escherichia coli* 055:B5; Sigma-Aldrich, MO) in 200μL of 1X PBS; Group II: PBS - 200μL of 1X PBS as a control; Group III: LPS+Rosi - received 10μg of LPS in 200μL of 1X PBS followed by 10mg/kg of Rosiglitazone 6 hours after the initial injection; and Group IV: Rosi - 10mg/kg of Rosiglitazone as a control. All
procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at Wayne State University (Protocol No. A 09-08-12).

**Macrophage isolation from murine myometrial and decidual tissues**

Eight hours after the first injection, the mice were euthanized and decidual and myometrial tissues were collected and processed immediately for (i) macrophage isolation and (ii) cryo-sectioning.

**Macrophage isolation**

Macrophages were isolated from the decidua and myometrium, as previously described (152). Briefly, the tissues were mechanically disaggregated using the Accutase cell dissociation reagent (Life Technologies, CA) and filtered using a 100μm cell strainer (Fisher Scientific, MA) to obtain single cell suspensions. The cells were then washed once with staining buffer [1X PBS (Fisher Scientific Bioreagents) containing 0.1% Bovine-serum albumin (Sigma Aldrich, MO) and 0.05% Sodium Azide (Fisher Scientific, MA)]. The cells were re-suspended in 96μL of staining buffer, with 4μL of an anti-mouse F4/80 antigen biotin (clone BM8, eBioscience, CA) and incubated at 4°C for 15 mins. After incubation, the cells were washed by centrifugation at 1250 x g for 7 min at 4°C. The cell pellet was re-suspended in 90μL of staining buffer containing 10μl of Streptavidin microbeads (Miltenyi Biotec, Germany) and again incubated at 4°C for 15 mins followed by 1 wash with 2ml of staining buffer. The resulting pellet was re-suspended in 500 μL of MACS (Miltenyi Biotech, Germany) buffer and F4/80⁺ cells (macrophages) were separated by positive selection using MS columns and a magnetic MACS separator. Macrophages were then washed with MACS buffer at 1250 x g for 7 min at 4°C. The resulting cell pellet was lysed using 400μL of RNeasy Lysis Buffer (Qiagen, Germany) and used for RNA isolation.
**RNA isolation and cDNA synthesis**

Total RNA was extracted (RNAeasy, Qiagen, Germany) following the manufacturer’s instructions. All the samples were simultaneously reverse transcribed using the iScript Reverse Transcription Supermix RT synthesis kit (Bio-Rad Laboratories, CA), per the manufacturer’s instructions. As the number of macrophages isolated from the murine tissues is very low, the amount of RNA extracted was also low. To increase the sensitivity and efficiency of qPCR, the target genes Tlr4, Ho-1, Nrf2 and housekeeping genes Gapdh, Tbp, Top1 were enriched by pre-amplification. The primers were obtained from IDT, and reconstituted with Tris-EDTA buffer (10mM Tris, 0.1mM EDTA, pH 8.0) to a 500µM working stock. 2.5µL from of each primer was mixed and the final volume was adjusted to 500 µL to create the pre-amplification primer cocktail (0.5µM). 10µL of the cDNA (25 ng) was mixed with 5µL of primer cocktail, 10µL of nuclease free water, and 25µL of pre-amplification master-mix (Sso – Advanced PreAmp Supermix, Bio-Rad Laboratories, CA). The mix was then cycled for 3 mins at 95°C, 15 seconds at 95°C and 4 mins at 58°C for 10 cycles.

**Real time PCR and data analysis**

The target genes Tlr4, Ho-1, Nrf2 and the housekeeping genes Gapdh, Tbp, Top1 were run in triplicates for each sample using 3µL of pre-amplified cDNA (diluted 1:30) per PCR reaction. The primers used are outlined in Table 2. Briefly, 3µL of cDNA template was mixed with 1µL primer (500nM), 1µL nuclease free water, and 5µL of Sybr-green master mix (LuminoCT, Sigma-Aldrich, MO). The PCR protocol used was: initial 95 °C for 5 min followed by 38 cycles of 95 °C for 15s and 60°C for 20s. The qPCR data was analyzed by the Pfaffl method using housekeeping genes as an internal reference (250, 251). Briefly, the mean C_T values of housekeeping genes per tissue sample was used to calculate the geometric mean C_T
value (Geo-mean $C_T$) and used as reference for the respective sample. The relative expression of target genes was calculated by using the formula $2^{\Delta C_T} = 2^{\Delta C_T}$, where $\Delta C_T = \text{Mean } C_T \text{ (Target gene)} - \text{Geo-mean } C_T$. The mean relative expression (MRE) of the target gene for each treatment groups was calculated by taking an average of the relative expression of individual tissue samples from the respective groups.

**Table 2: Sequences of primer used for gene expression in macrophages**

<table>
<thead>
<tr>
<th>Gene Name</th>
<th>Gene Symbol</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glyceraldehyde 3-phosphate dehydrogenase</td>
<td>Gapdh</td>
<td>$5'$-AAT GGT GAA GGT CGG TGT G-3'</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$5'$-GTG GAG TCA TAC TGG AAC ATG TAG-3'</td>
</tr>
<tr>
<td>Topoisomerase-1</td>
<td>Top1</td>
<td>$5'$-CTT TAA TTC GTG GCG GAC TAG A-3'</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$5'$- AGA CAA GGA ACG AAA GGA G-3'</td>
</tr>
<tr>
<td>TATA Box Binding Protein</td>
<td>Tbp</td>
<td>$5'$-TTC ACC AAT GAC TCC TAT GAC C-3'</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$5'$-CAA GTT TAC AGC CAA GAT TCA CG-3'</td>
</tr>
<tr>
<td>Toll like receptor - 4</td>
<td>Tlr4</td>
<td>$5'$-GAA GCT TGA ATC CCT GCA TAG-3'</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$5'$-AGC TCA GAT CTA TGT TCT TGG TTG-3'</td>
</tr>
<tr>
<td>Heme oxygenase -1</td>
<td>Ho-1</td>
<td>$5'$-ACA CTC TGG AGA TGA CAC CT-3'</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$5'$-TTG TGT TCC TCT GTC AGC ATC-3'</td>
</tr>
<tr>
<td>Nuclear factor (erythroid-derived 2)-like 2</td>
<td>Nrf2</td>
<td>$5'$-CCT TGT ACT TTG AAG ACT GTA TGC-3'</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$5'$-GAG GGA CTG GGC CTG AT-3'</td>
</tr>
</tbody>
</table>

**Immunofluorescence staining**

Myometrial and decidual tissues (n = 5 each) were immediately frozen in Tissue-Tek O.C.T Compound (Sakura Finetek, CA). The tissues were sectioned into 10µm sections and placed on Fisherbrand Superfrost Plus microscope slides (Thermo Scientific, MA). For staining, the tissues were fixed in 4% paraformaldehyde for 10 mins and washed in 1X PBS containing 0.1% Tween-20. The tissues were then permeabilized with 0.25% Triton X-100 in 1X PBS for 10 min. Nonspecific antibody interactions were blocked using donkey serum (Jackson Immunoresearch, PA) at room temperature for 1 hour. Slides were then incubated with the following: anti-TLR4 antibody, anti-HO-1 antibody (Abcam, UK), anti-NRF2 antibody (Cell Signaling, MA) at 4°C overnight. The following day, the slides were washed 3 times (5 minutes/wash) with 1X PBS containing 0.1% Tween 20. The slides were incubated with 2
mg/mL of goat anti-rabbit secondary antibody conjugated to Alexa Fluor 594 (Jackson Immunoresearch, PA) at room temperature for 1 hour. The slides were washed again with 1X PBS containing 0.1% Tween 20, and incubated with 2 mg/mL of rat anti-mouse F4/80 antibody conjugated to FITC (1:100, Abcam, UK) at room temperature for 2 hours. Post incubation, the slides were again washed 3 times and stained with DAPI (Room temperature for 20 mins). The slides were given a final wash and mounted in Vectashield Mounting Medium (Vector Laboratories, CA). Immunofluorescence was visualized using the Leica DM IRB epifluorescence microscope (Leica, Germany), and images were captured using a Hamamatsu Orca digital camera (Hamamatsu Corp, Japan).

Results

Macrophage populations

Macrophages were isolated from the decidual and myometrial tissues of mice treated with LPS only (LPS), LPS + Rosiglitazone (LPS + Rosi), Rosiglitazone only (Rosi), and PBS only (PBS). The purity of the isolated F4/80+ macrophage cells was assessed by flow cytometry. The percentage of macrophages isolated from the decidual and myometrial tissues was 84.9% and 88.6% respectively (Figure 8A and B).

Figure 8: Purity of isolated macrophages from decidual and myometrial tissues. Decidual (A) and myometrial (B) macrophages (F4/80+ cells) were isolated by magnetic cell sorting, and purity was evaluated by flow cytometry. The red histogram represents the auto-fluorescence control and the turquoise histogram represents isolated macrophages from decidua or myometrial tissues.
**Rosiglitazone downregulated LPS-induced Tlr4 expression**

Total RNA was extracted from decidual and myometrial macrophages isolated from mice from LPS, LPS + Rosi, Rosi, and PBS groups and converted to cDNA. The expression of the Tlr4 receptor was assessed using qPCR.

The mean relative expression (MRE) of Tlr4 in decidual macrophages isolated from mice injected with endotoxin alone was significantly higher compared to those isolated from mice injected with PBS only (1.81 ± 0.23 vs 1.23 ± 0.10; p=0.031). The MRE of decidual macrophages from mice injected with Rosiglitazone only was significantly reduced compared to those isolated from mice injected with endotoxin alone (0.96 ± 0.08 vs 1.81 ± 0.23; p=0.007). The MRE of decidual macrophages isolated from LPS injected mice treated with Rosiglitazone was significantly lower compared to those isolated from mice injected with endotoxin alone (1.14 ± 0.18 vs 1.81 ± 0.23; p=0.048). However, no significant differences were observed in the Tlr4 expression of isolated macrophages from mice injected with PBS and Rosiglitazone alone (Figure 9A).

In line with the observation in decidual macrophages, the MRE of Tlr4 in myometrial macrophages isolated from mice injected with endotoxin alone was significantly higher compared to those isolated from mice injected with PBS only (2.29 ± 0.24 vs 1.25 ± 0.11; p=0.007) and Rosiglitazone only (2.29 ± 0.24 vs 1.44 ± 0.10; p=0.031). The MRE of Tlr4 in myometrial macrophages isolated from LPS injected mice treated with Rosiglitazone was significantly lower compared to those isolated from mice injected with endotoxin alone (1.20 ± 0.19 vs 2.29 ± 0.24; p=0.015) (Figure 9B).

Typically, the number of isolated macrophages is too low for conventional quantitative protein assessment by western blotting. Hence, we decided to assess TLR4 protein expression
by immunohistochemistry (235). The cryo-fixed decidual and myometrial tissues from mice injected with LPS only, LPS + Rosiglitazone, Rosiglitazone only, and PBS only were sectioned and stained with F4/80+ and TLR4 antibodies. The presence of F4/80 and TLR4 was observed in both decidual and myometrial tissues. The relative expression of TLR4 was higher in myometrial and decidual tissues from mice injected with endotoxin compared to controls injected with PBS and Rosiglitazone only (Figures 9C and D).

**Figure 9: Rosiglitazone downregulates LPS induced TLR4 expression.** Mean relative expression of Tlr4 mRNA in decidual (A) and myometrial (B) in macrophages isolated from animals (n=4-7) in the 4 treatment groups. Macrophages from the LPS treated group showed increased expression of TLR4 which was significantly downregulated when Rosiglitazone was administered. Representative images show immune-staining for TLR4 protein expression (red) in (C) decidual and (D) myometrial macrophages (green, arrows). The nuclei were stained with DAPI (blue). Data are shown as box plots (median). *,# indicates significance at p<0.05 when compared to the LPS group and PBS group respectively. Scale bar: 50µM, Magnification is 1000X, n=3.
Treatment with Rosiglitazone inhibited the LPS mediated downregulation of Nrf2 expression

NRF2 is the master transcription factor that regulates oxidative stress via the expression of anti-oxidant factors (252)(253). Therefore, to evaluate the oxidative stress signaling pathway in an endotoxin-induced model of preterm birth, we assessed NRF2 expression in isolated myometrial and decidual macrophages from mice injected with LPS only, LPS + Rosiglitazone, Rosiglitazone only, and PBS only.

The MRE of $Nrf2$ in decidual macrophages isolated from mice injected with endotoxin was significantly lower compared those isolated from mice injected with PBS ($2.10 \pm 0.22$ vs $3.28 \pm 0.30; \ p=0.028$) and Rosiglitazone alone ($2.10 \pm 0.22$ vs $3.28 \pm 0.37; \ p=0.028$). The MRE of $Nrf2$ in decidual macrophages isolated from LPS injected mice treated with Rosiglitazone was significantly increased compared to those isolated from mice injected with endotoxin alone ($3.15 \pm 0.2$ vs $2.10 + 0.22; \ p=0.028$). The MRE of $Nrf2$ was comparable between decidual macrophages isolated from mice treated with LPS + Rosiglitazone, PBS, and Rosiglitazone alone (Figure 10A).

A similar trend in $Nrf2$ expression was observed in myometrial macrophages. The MRE of $Nrf2$ in myometrial macrophages isolated from mice injected with endotoxin was significantly lower compared to those isolated from mice injected with PBS ($1.37 \pm 0.16$ vs $2.31 \pm 0.18; \ p=0.028$) and Rosiglitazone only ($1.37 \pm 0.16$ vs $2.51 \pm 0.29; \ p=0.015$). In addition, the expression of $Nrf2$ in myometrial macrophages isolated from LPS injected mice treated with Rosiglitazone was, significantly higher than those injected with endotoxin alone ($2.80 \pm 0.49$ vs $1.37 + 0.16; \ p=0.031$) (Figure 10B). $Nrf2$ expression levels were comparable between myometrial macrophages isolated from LPS injected mice treated with Rosiglitazone and those isolated from mice injected with PBS and Rosiglitazone alone.
Figure 10: Rosiglitazone recuses LPS mediated downregulation of NRF2 expression. Mean relative expression of Nrf2 mRNA in decidual (A) and myometrial (B) macrophages isolated from animals (n=4-7) in the 4 treatment groups. Macrophages from the LPS treated group showed a significantly lower expression of Nrf2, which was rescued to control levels when Rosiglitazone was administered. Representative images show immune-staining for NRF2 protein expression (red) in (C) decidual and (D) myometrial macrophages (green, arrows). The nuclei were stained with DAPI (blue). Data are shown as box plots (median). ‘*’ ‘#’ ‘ψ’ indicates significance at p<0.05, when compared to the LPS group, PBS group and ROSI group respectively. Scale bar: 50µM, Magnification is 1000X, n=3

Visualization of the NRF2 protein was performed using immunohistochemistry. Neither decidual nor myometrial tissues from mice injected with LPS endotoxin expressed the NRF2 protein; however, a comparable expression of NRF2 was observed in decidual and myometrial tissues from LPS injected mice treated with Rosiglitazone and those from mice injected with PBS and Rosiglitazone alone (Figures 10C and D).
Treatment with Rosiglitazone inhibited the LPS mediated reduction of Ho-1 expression

The mRNA expression of *Ho-1*, a known downstream target for NRF2 signaling and a critical anti-oxidant mediator in cells, was assessed in decidual and myometrial macrophages (253). The MRE of *Ho-1* in decidual macrophages isolated from mice injected with endotoxin was significantly lower compared to those isolated from mice injected with PBS (0.11 ± 0.02 vs 0.21 ± 0.004; p=0.028) and Rosiglitazone only (0.11 ± 0.02 vs 0.42 ± 0.09; p=0.015).

The *HO-1* expression in decidual macrophages isolated from LPS injected mice treated with Rosiglitazone was significantly higher compared to those isolated from mice injected with endotoxin alone (0.50 ± 0.10 vs 0.11 ± 0.02; p=0.015). Interestingly, the *HO-1* expression of decidual macrophages isolated from LPS injected mice treated with Rosiglitazone was significantly elevated compared to those isolated from PBS controls (0.50 ± 0.10 vs 0.21 ± 0.004; p=0.0159). The *HO-1* expression in isolated decidual macrophages from mice injected with Rosiglitazone alone was also significantly higher compared to PBS controls (0.42 ± 0.09 vs 0.21 ± 0.004; p=0.015) (Figure 11A).

In contrast to decidual macrophages, *HO-1* expression in myometrial macrophages isolated from mice injected with endotoxin was not significantly different compared to PBS controls (0.26± 0.020 vs 0.22± 0.04; p=0.45). However, *HO-1* expression in isolated myometrial macrophages from LPS injected mice treated with Rosiglitazone was comparable to those isolated from the decidua. The MRE of *Ho-1* in isolated myometrial macrophages from mice injected with LPS+ Rosiglitazone was significantly higher compared those isolated from mice injected with endotoxin (0.53± 0.06 vs 0.26± 0.020; p=0.03) and PBS alone (0.53± 0.06 vs 0.22+0.04; p=0.015). The MRE of *Ho-1* in myometrial macrophages isolated from mice injected with Rosiglitazone alone was elevated compared to those isolated from LPS-injected mice (0.46 ±
0.06 vs 0.26+ 0.02) and PBS controls (0.46 + 0.06 vs 0.22+ 0.04); yet, these values were not statistically significant (Figure 11B).

**Figure 11: Rosiglitazone rescued LPS mediated decrease in HO-1 expression.** Mean relative expression of Ho-1 mRNA in decidual (A) and myometrial (B) macrophages isolated from animals (n=4-7) in the 4 treatment groups. Macrophages from the LPS treated group showed a lower expression of Ho-1, which was significantly upregulated when Rosiglitazone was administered. Representative images show immune-staining for HO-1 protein expression (red) in (C) decidual and (D) myometrial tissues macrophages (green, arrows). The nuclei were stained with DAPI (blue). Data are shown as box plots (median). ‘*’ ‘#’ ‘ψ’ indicates significance at p<0.05, when compared to the LPS group, PBS group and ROSI group respectively. Scale bar: 50µM, Magnification is 1000X, n=3

The relative protein levels of HO-1 observed in myometrial tissues also supported the mRNA expression data. HO-1 was expressed in myometrial and decidual macrophages isolated from LPS injected mice treated with Rosiglitazone as well as those isolated from mice injected with PBS and Rosiglitazone alone. A reduced expression of HO-1 was observed in myometrial
and decidual tissues from mice injected with endotoxin compared to those injected with LPS+ Rosiglitazone and PBS and Rosiglitazone alone (Figures 11C and D).

Discussion

In the current study, we expanded the involvement of molecular pathways in the response to Rosiglitazone treatment in a murine model of LPS induced PTB. Our previous study showed that administration of Rosiglitazone reduced the rate of LPS induced preterm birth by 30%, increased the pup viability by 41% and lowered systemic & local inflammation (235). We also showed a downregulation of the NF-κB pathway mediators – TNF-α and NF-κB1- in decidual and myometrial macrophages. These findings demonstrated that treatment with Rosiglitazone contributes to reduced inflammation via reducing Nf-κB activity in local macrophages. Herein, we investigated whether treatment with Rosiglitazone also regulated TLR4 expression and induced the expression of the anti-oxidants HO-1 & NRF2, which could further support the reduction of PTB and pup mortality.

Depletion of macrophages in pregnant mice abrogates the effects of LPS and prevents PTB (155), suggesting that these innate immune cells are involved in mediating the effects of LPS. Therefore, we focused on the role of macrophages in our LPS induced model of preterm birth. Decidual and myometrial macrophages from mice injected with LPS only, LPS + Rosiglitazone, Rosiglitazone only, and PBS only were isolated and their gene expression was analyzed by qPCR. The protein expression was assessed by staining decidual and myometrial tissues with antibodies against F4/80+ and the proteins of interest. We observed a significant increase in Tlr4 expression in both decidual and myometrial macrophages from mice injected with endotoxin compared to those isolated from mice injected with PBS and Rosiglitazone alone. Administration of Rosiglitazone post LPS prevented this upregulation and macrophages from the
LPS + Rosi group had TLR4 levels (protein and mRNA) comparable to those seen in control groups, suggesting an active regulation of TLR4 in our model.

Induction of Tlr4 expression by LPS has been observed in smooth muscle cells and microglia; however, information on the expression of this protein in mouse decidual and myometrial tissues and tissue macrophages is inconclusive (216, 254, 255). Salminen et al reported TLR4 mRNA expression in the uteri of pregnant mice; however, its expression significantly declined post LPS treatment (256). In-vitro studies in mouse macrophages showed no alteration in TLR4 expression after LPS treatment whereas human mononuclear cells showed an upregulation at the mRNA level with no alteration in protein expression (257)(258). In contrast, we observed that the LPS upregulated TLR4 mRNA expression and protein in macrophages from both tissues. These results suggest that LPS regulates the expression of its own receptor in these cells. Increased expression of TLR4 is associated with increased sensitivity to LPS and increased activation of inflammatory pathways e.g. NF-κB (254). In return, we suggest that Rosiglitazone mediated the downregulation of TLR4 expression (as observed in the LPS + Rosi group) and impaired the activation of pro-inflammatory pathways, which could ultimately contribute to a reduction in PTB (259). Further, in both decidual and myometrial tissues, the TLR4 protein was exclusively localized in the macrophages (F4/80⁺ cells) (Figure 9C, D). While it is known that human decidual cells express the TLR4 protein, its expression in mouse decidual tissue remains unknown (260). We report that in murine decidual and myometrial tissues, only the macrophages express the TLR4 receptor, suggesting an active role in pathogen recognition and clearance during pregnancy.

In addition to activation of NF-κB, TLR4 activation has been shown to induce production of reactive oxygen species (ROS), which leads to oxidative stress (261). Oxidative stress in an
inevitable part of pregnancy and in normal circumstances, a balance between the production of ROS and the anti-oxidants that scavenge them is maintained. However, excess ROS – induced by inflammation or lowered anti-oxidant capacity- leads to oxidative stress damage which has been associated with pathologies like PE, IUGR and PTB [detailed review in (84, 262)]. Further, elevated ROS has been shown to augment the expression of TLR4 in mice which, in turn, has been shown to downregulate the expression of anti-oxidant enzyme HO-1. These data suggest that there is a mutual regulation between inflammatory and oxidative stress pathways (263-265).

The transcription factor NRF2 is the master regulator of anti-oxidant enzyme expression and is induced under normal cellular stress conditions by various ROS (252) (252, 253). Activation of NRF2 leads to its release from the cytoplasmic inhibitor Kelch Like ECH Associated Protein 1 (Keap-1) and translocation to the nucleus where it induces expression of anti-oxidant enzymes like HO-1, which then help in scavenging ROS and other oxidants. NRF2 has been reported to play a role in murine placental development (266). Its activation was shown to reduce thrombin induced PTB, suggesting its active role in inflammation induced PTB. HO-1 has also been implicated in playing crucial roles during pregnancy (267, 268). It was reported to regulate recruitment and maintenance of myeloid cells in pregnant uteri and placental vasculature development (269, 270). Additionally, HO-1 activation via statins was shown to delay myometrial contractions, cervical ripening and inhibit pathological complement activation in the LPS induced PTB model (271). However, expression of both HO-1 and NRF2 in myometrial and decidual tissues and tissue macrophages has not been described.

We observed that LPS treatment downregulated the expression of both NRF2 and its downstream target HO-1. These results demonstrate, for the first time, that LPS actively inhibits the anti-oxidant response in the pregnant mice by downregulating NRF2. Thus, LPS mediated
inflammation contributes to the elevated oxidative stress in this model. As reported in other cell systems, Rosiglitazone treatment induced the expression of both NRF2 and HO-1. In addition, the expression of these proteins in the LPS + Rosiglitazone group was comparable to that in the PBS and Rosiglitazone groups (249). A cross talk between the NRF2-HO-1 signaling and TLR4-NF-κB signaling pathway has been suggested and activation of NRF2 has been shown to rescue the effects of TLR4 mediated pro-inflammatory pathways in mouse liver and adipose tissue cells (272-274). We suggest activation of a similar pathway due to Rosiglitazone administration in our model.

Furthermore, HO-1 expression was significantly upregulated in decidual macrophages isolated from mice injected with Rosiglitazone only, suggesting its regulation by a NRF2 independent mechanism. Similar to TLR4, the NRF2 and HO-1 proteins were predominantly localized to macrophages from decidual and myometrial tissues, suggesting their role in mediating the oxidative and inflammatory stress cross talk.

Taken together, our results demonstrate that LPS might promote inflammation and oxidative stress by upregulating TLR4 expression and downregulating the anti-oxidants NRF2 and HO-1 in the LPS induced model of PTB. In addition, Rosiglitazone prevents PTB by downregulating TLR4 mediated pro-inflammatory signaling and upregulating the anti-oxidant response via NRF2 and HO-1.

**Limitations of Aim 1**

The current study evaluated the effects of Rosiglitazone intervention in preventing endotoxin induced PTB in mice via its effects on inflammatory and anti-oxidative pathways. However, Rosiglitazone has been known to contribute to PPARγ activity in several metabolic and cell differentiation pathways. Evaluating the effects of Rosiglitazone intervention on these
pathways would provide further insights into the efficacy of intervention. Further, the current study focused on macrophages as they are the critical cell type involved in LPS mediated PTB. Assessing the effects of PPARγ activation in other immune cell types – NK cells, neutrophils – would help in better understanding of the intervention model.
CHAPTER 4 - PPARγ ACTIVATION RESCUES ENDOTOXIN MEDIATED EFFECTS ON TROPHOBLAST INFLAMMATORY RESPONSE AND DIFFERENTIATION IN 1ST TRIMESTER HUMAN PLACENTA

Introduction

Crosstalk between inflammatory and trophoblast differentiation pathways at the maternal fetal interface is crucial for successful establishment and maintenance of pregnancy. The trophoblast cells of the placenta play a critical role in maintaining allogenic tolerance by selective expression of cell surface receptors such as HLA-E, HLA-G and HLA-C (275, 276). They prevent fetal rejection by suppressing local inflammatory responses via regulation of T cell populations and impairing responses to immune-activating cytokines present at the maternal fetal interface (19, 277, 278). Additionally, trophoblast cells express pattern recognition receptors like Toll like receptors (TLR’s) and Nod like receptors (NLR’s) which are known to be involved in pathogen recognition (26, 279). Upon ligation, these receptors initiate an inflammatory cascade via transcription factors like NF-κB, AP-1 and STAT3 to eliminate pathogens (26, 280, 281). Furthermore, the uterine NK cells and macrophages at the site of implantation direct trophoblast migration and invasion. They secrete several cytokines and chemokines that contribute to a local environment of growth factors at the maternal fetal interface (282, 283). These cytokines play a role in trophoblast differentiation (invasive extravillous trophoblast phenotype), inducing secretion of matrix degrading enzymes and selective remodeling of uterine spiral arteries (283-285). The proinflammatory transcription factor NF-κB was recently shown to regulate expression of Placental growth factor (PlGF) – a protein known for its role placental angiogenesis, trophoblast proliferation. PlGF as well initiates differentiation towards the invasive phenotype further highlighting the role of inflammatory mediators in trophoblast function (286, 287). Dysregulation in these complementary processes could affect pregnancy success. Elevated inflammation at the maternal–fetal interface and abnormal placental function are both
common features in several pregnancy pathologies (288). Localized inflammation (Chorioamnionitis) has been reported to be present in >85% spontaneous preterm births even in the absence of systemic inflammation (289). Elevated placental cytokine release has been observed in cases of both preterm birth (PTB) and PE (290-294). Furthermore, proinflammatory cytokines like TNF-α and IL-6 released as a part of inflammatory cascade have been shown to induce trophoblast cell apoptosis as well commonly found in placentas from IUGR and PE cases (293, 295-297). Understanding the mutual molecular mechanism between inflammation and trophoblast differentiation could provide further insights into the etiologies of above mentioned syndromes. It could as well potentially highlight molecular targets common to both pathways which can then be evaluated for development of therapeutic strategies.

*In vitro* studies have shown that exposure to inflammatory stimuli induces proinflammatory cytokine secretion from trophoblast cells (298, 299). Additionally, exposure to proinflammatory cytokines such as TNF-α, IL-6 induced trophoblast cell apoptosis and affected trophoblast invasion, although contradictory results were reported by various groups (300, 301). Jovanovic, M et al. reported that proinflammatory cytokines increased invasion in both isolated human primary trophoblast cells as well as HTR cells, whereas other groups reported an overall decrease in invasion (300-302). To date, the effects of inflammation on trophoblast differentiation and related proteins including transcription factors has not been explored.

Trophoblast differentiation is a tightly regulated process. The transcription factor PPARγ recently emerged as an important protein in early trophoblast lineage differentiation as well as placental function. Initially known for its role in energy metabolism and anti-inflammatory processes, PPARγ knockouts were shown to die in-utero due to placental abnormalities (178, 212). It was reported to regulate the transcription factor Glial cell missing-1 (GCM1) and the
glycoprotein hormone human chorionic gonadotropin (CG-β); both known to be crucial players in trophoblast differentiation (69, 78, 303).

Our group recently showed that activation of PPARγ in a mouse model of inflammation induced preterm birth prevented premature delivery, reduced systemic and local inflammation by repressing NF-κB activity and improved placental and fetal weights, further emphasizing its role in placental function and as an anti-inflammatory agent (235, 304). Surprisingly, the role of PPARγ in inflammation mediated effects on trophoblast differentiation in 1st trimester human placenta so far has not been evaluated.

In the current study, we therefore aimed to measure the effects of inflammation on trophoblast differentiation and the potential role of PPARγ in this process. We hypothesized that activation of PPARγ would reverse the inflammation mediated effects on trophoblast differentiation.

We applied the commonly used bacterial endotoxin lipopolysaccharide (LPS) to induce the inflammatory cascade and the drug Rosiglitazone (specific PPARγ agonist) to induce PPARγ activity in a 1st trimester placental explant culture model. We assessed the effects of LPS mediated inflammation and PPARγ activity by (i) measuring the rate of apoptosis and proliferation in trophoblast cells (ii) evaluating expression of differentiation related markers (GCM1 and CG-β), and (iii) analyzing trophoblast function by studying invasion capacity.

Materials and Methods

Tissue collection

Human first trimester placental tissues (5-12 weeks) were obtained with written informed consent from healthy pregnant women following elective termination of pregnancy at the Michigan Family planning facility, Michigan, US and Morgentaler Clinic, Toronto, Canada. The
Institutional Review Board (IRB) of Wayne State University and Mount Sinai Hospital (MSH) Research Ethics Board approved all consent forms and protocols used in this study.

**First trimester explant culture**

The chorionic villi from 1st trimester human placenta were micro-dissected under a microscope into small pieces (20-30 mg wet weight) as previously described in (79) and cultured in 1ml of Dulbecco's Modified Eagle Medium – F12 (DMEM/F12) media, without phenol red (Life Technologies, CA) containing 10% Fetal bovine serum (FBS, Atlanta Biologicals, GA) and 1% Antibiotic-Antimycotic (Life Technologies, CA). The explants were treated in triplicates, by adding the respective treatments to the culture medium and then incubating at 8% O₂, 37°C for 24 hrs. After 24 hrs, the explants were weighed and snap frozen to be used later for either RNA extraction or protein analysis. One replicate was fixed in 4% paraformaldehyde (PFA, Fischer Scientific, MA) for 60 minutes and paraffin embedded to be used for immunohistochemistry. The media was frozen and used for ELISA.

**Cell culture**

The HTR-8/SVneo cytotrophoblast cell line (passage number 25-35) was cultured on plastic in T-75 tissue culture flasks (Corning) in DMEM/F12 media (Life Technologies, CA) containing 10% Fetal bovine serum (Atlanta Biologicals, GA) and 1% Antibiotic-Antimycotic (Life Technologies, CA) in a humidified incubator at 5% CO₂. Culture medium was replaced with serum-free medium prior to all treatments (305).

**Explants and cell culture treatments**

LPS (*Escherichia coli* 055: B5; Sigma-Aldrich, MO) was reconstituted in sterile 1X Phosphate buffered saline (PBS) (Life technologies, CA) and stored at -20°C. Cell or villous explant cultures were treated by supplementing culture medium with 1µg/ml LPS in presence or
absence of 10µM Rosiglitazone (Sellekchem, MA). Cells/explants treated with 1X PBS and 10µM Rosiglitazone were used as controls. The treatment groups will be identified as outlined in Table 3 in the rest of the chapter. In addition to these, HTR-8/SV Neo cells were also treated with 100nM 2-[(Aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophencarboxamide (TPCA-1) (Tocris, UK), a specific inhibitor for NF-κB activity.

Table 3: Trophoblast explants/cell treatment groups and names.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Group Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>LPS - 1µg/ml</td>
<td>LPS/Endotoxin</td>
</tr>
<tr>
<td>LPS - 1µg/ml + Rosiglitazone- 10µM</td>
<td>LPS + Rosi</td>
</tr>
<tr>
<td>1X PBS</td>
<td>Control</td>
</tr>
<tr>
<td>Rosiglitazone- 10µM</td>
<td>Rosi</td>
</tr>
</tbody>
</table>

**RNA extraction and real time PCR**

The explants/cells were lysed in 0.9 ml Qiazol (Qiagen, Germany). Total RNA was extracted (RNAeasy Plus Universal Mini kit, Qiagen, Germany) and all samples were simultaneously reverse transcribed using the RT synthesis kit from Bio-Rad per the manufacturer’s protocol (iScript Reverse Transcription Supermix, Bio-Rad Laboratories, CA). Real-time PCR was performed on the Bio-Rad CFX384 real time system in triplicates in 10uL total reaction volume containing 10 ng of template cDNA, 5µL of SYBR-green master mix (LuminoCT, Sigma-Aldrich, MO) and 500nM of primers. The primers used for assessing the expression levels of target and housekeeping genes are outlined in Table 4. Data was analyzed using the delta delta CT method as described in (251).
Table 4: List of primer sequences used for studying expression levels of trophoblast differentiation markers

<table>
<thead>
<tr>
<th>Gene Name</th>
<th>Gene Symbol</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytochrome - C 1</td>
<td>Cyc1</td>
<td>5'-CAT CAT CAA CAT CTT GAG CC-3'</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5'-CAG ATA GCC AAG GAT GTG TG-3'</td>
</tr>
<tr>
<td>Tyrosine 3-monooxygenase</td>
<td>Ywh</td>
<td>5'-CCG CCA GGA CAA ACC AGT AT-3'</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5'-ACT TTT GGT ACA TTT TGG CTT CAA -3'</td>
</tr>
<tr>
<td>TATA Box Binding Protein</td>
<td>Tbp</td>
<td>5'-CAC ATC ACA GCT CCC CAC CA-3'</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5'-TGCA GGA GCC AAG AGT GAA-3'</td>
</tr>
<tr>
<td>Glial cell missing 1</td>
<td>Gcm1</td>
<td>5'-TGA ACA CAG AAC CCT CTT C-3'</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5'-CCA CTG TAA CTA CCA GGC AAT-3'</td>
</tr>
<tr>
<td>Human chorionic gonadotropin - beta</td>
<td>CG-β</td>
<td>5'-GGT TGA GGC TTC AGT CCA G-3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5'-AGG GAG TAG GGT GTA GGA AG-3'</td>
</tr>
</tbody>
</table>

**Protein extraction and western blotting**

Total proteins were extracted from the explants by homogenizing the explants in lysis buffer containing: 1% (w/v) SDS, 50mM Tris, pH 6.8 and 10mM NEM followed by heating the lysate at 100°C for 10 mins. The lysates were then spun at 10,000 rpm for 15 mins and the supernatant was collected. Protein concentration was then determined using Pierce® 660 nm protein assay reagent (Thermo Scientific, MA), per manufacturer’s instructions. Purified protein (30mg) was separated on 12% SDS-polyacrylamide gel (TGX Stain Free Fastcast Acrylamide kit, Bio-Rad Laboratories, CA) and transferred on PVDF membrane (Bio-Rad Laboratories, CA). Membranes were blocked with 5% skimmed milk in Tris-buffer saline (TBST) containing 0.1% (v/v) Tween for 1hr at room temperature (RT) and incubated over night at 4°C with the anti-GCM1 antibody (1:3000) (Aviva System Biology, UK). The membranes were washed with TBST and incubated with a HRP-conjugated secondary antibody (Cell signaling) for 1 hr. at RT. The antibody binding was detected using the Western Lightning® ECL Pro detection kit (Perkin Elmer, MA). Signals were visualized using a ChemiDoc Imaging System (Bio-Rad Laboratories, CA) and Image Lab V.5.1 software (Bio-Rad Laboratories, CA). Densities of immunoreactive bands were measured as arbitrary units by ImageJ software. Protein levels were normalized to a housekeeping protein β-actin (1: 20,000; Abcam, UK).
**Enzyme Linked Immunosorbent Assay**

The media collected from placental explant cultures was assayed for levels of secreted inflammatory cytokines – IL-6, IL-8, IL-1β, TNF-α, CCL5 using the Duo Set ELISA development kits (R & D Systems) as per the manufacturers protocol. The levels of CG-β were assayed using the Beta-Human Chorionic Gonadotrophin (β-hCG), free (Human) - ELISA Kit (Phoenix Pharmaceuticals, CA) again as per the manufacturer’s protocol. The optical density of the final colored reaction product was measured at 450nm using multispectral UV/VIS plate reader (Bio-Tek, VT). Standard curves were used to calculate protein in content in the samples. The level of proteins detected was divided by the weight of the explant to obtain the amount of protein secreted per milligram of explant tissue. The data was then normalized to control treatment to take sample to sample variations into account. The data was analyzed using the Graph pad prism 7.0 software.

**Immunohistochemistry**

Immunostainings of placental villi were performed as described before (306). Briefly, the sections were deparaffinized and rehydrated, followed by antigen retrieval using Dako Target retrieval solution (Agilent-DAKO, CA). The intrinsic peroxidase activity was then quenched by incubating the sections with 3% Hydrogen peroxide (Fisher Scientific, MA) for 30 mins at RT, followed by a wash with 1X PBS. The sections were then incubated overnight at 4°C with anti-PCNA (Santa Cruz, TX), or 10μg/ml nonimmune Rabbit IgG (Jackson Immunoresearch, PA) (used as a negative control). On the following day, the slides were washed 3 times (5 minutes/wash) with 1X PBS containing 0.1% Tween 20. The samples were then incubated for 30 min with a peroxidase-conjugated polymer coupled to anti-rabbit IgG (EnVision Systems Peroxidase, Agilent-DAKO, CA). The peroxidase was visualized with 3,3-diaminobenzidine
(DAB, Agilent-DAKO, CA) and hydrogen peroxide for 5 min. Tissues were counterstained with hematoxylin, dehydrated and were cover slipped. The staining was visualized using Nikon Eclipse 90i epifluorescence microscope (Nikon Inc., Japan) and the images were analyzed using ImageJ software.

HTR-8/SV neo cells were fixed with 4% PFA in 1X PBS for 10 mins at RT, washed 3 times with 1X PBS (5 mins/wash) and permeabilized with PBS containing 0.1% Triton-X100 for 10 mins. Cells were then incubated overnight at 4°C with various primary antibodies against: anti-Integrin alpha 1 (EMD Millipore, MA), and anti-Integrin alpha 6 (Cell Signaling Technologies, MA) or 10 μg/ml of nonimmune mouse serum (Jackson Immunoresearch, PA), the next day cells were washed 3 times with 1X PBS (5 mins/wash) and incubated with peroxidase-conjugated polymer coupled to anti-mouse IgG (EnVision Systems Peroxidase, Agilent - DAKO, CA). The peroxidase was visualized with 3,3-diaminobenzidine (DAB, Agilent - DAKO, CA) and hydrogen peroxide for 5 min. The cells were then imaged using the Leica DM IRB epifluorescence microscope (Leica, Germany), and images were captured using a Hamamatsu Orca digital camera (Hamamatsu Corp, Japan). All samples were stained similarly to avoid staining bias.

To quantify the staining intensity, monochromatic bright field images of the antibody/DAB stained cells were obtained at ×400. Before imaging the brightness was adjusted in a region of each slide devoid of tissue/cells by setting the gray level to 255. Using Simple PCI imaging software (Hamamatsu Corp, Japan), 5 random fields were imaged per well and the mean gray level was determined. The intensity from 5 images fields was averaged to obtain the mean intensity per well and the intensity from 3 wells was combined to get the average intensity per treatment.
**Matrigel invasion assay**

For placental explants, individual clusters of 6–8 week villi were dissected under a stereomicroscope and verified for the presence of extravillous trophoblasts (EVT’s) on the villous tips. These clusters were cultured on Millicell-CM inserts (12-mm diameter, 0.4-μm pores; EMD Millipore, MA) precoated with 0.2 mL of undiluted Matrigel (Corning, MI) in a 24-well culture plate for a total of 72 hours. The bottom chamber contained 300μL DMEM/F12 (Life Technologies, CA) without serum, medium supplemented with 10% Fetal bovine serum (Atlanta Biologicals, GA) and 1% Antibiotic-Antimycotic (Life Technologies, CA). The upper chamber contained approximately 200μL of the same medium. The explants were treated by supplementing the media with respective drugs. The explants were imaged every 24 hrs. for 72 hrs using Hamamatsu Orca digital camera (Hamamatsu Corp, Japan) and the outgrowths were measured using the ImageJ software. Each treatment was performed in duplicates for every tissue, and the experiment was repeated 3 times.

For assessing invasion of cell line, HTR-8/SV Neo cells (100,000) were cultured with treatments outlined in Table 3 on matrigel in 6.5mm Transwell inserts as previously reported in (305). Briefly, 15μL of undiluted growth factor reduced matrigel was added onto the membrane and the inserts were placed into 24-well culture plates and incubated at 37°C for 1 hr. for polymerization. After gel formation, the lower chamber was filled with 500 ml of serum-free DMEM/F12 medium and approximately 100,000 cells were cultured at 20% O₂ & 37°C for 24hrs on the matrigel in 100μL of medium. Cells that penetrated the matrigel and populated the lower chamber were detached using 500μL Trypsin-EDTA solution (Life technologies, CA). The number of invading cells in response to treatment was quantified by microscopic imaging of 5 random fields per well and averaging the number of cells counted per field. Each treatment was
performed in duplicates and the entire experiment was repeated 3 times. The calculation was performed by combining the average number of cells for each treatment across all experiments.

**TUNEL assay**

For histological evaluation and quantification of apoptosis in paraffin embedded sections DNA strand breaks were detected by terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end-labeling (TUNEL), using a fluorescein-based in situ cell death detection kit (Roche Applied Science, IN), per the manufacturer's instructions. Sections were imaged with a Nikon Eclipse 90i epifluorescence microscope (Nikon Inc., NY). The apoptotic trophoblast cells (TUNEL-positive nuclei) were counted at 200× from 5 random fields on each section from three samples for each treatment, along with the total number of nuclei (DAPI-labeled) to calculate the percentage of TUNEL/DAPI-labeled nuclei (TUNEL index). Sections subjected to treatment without TdT were assessed as negative controls. The calculation was performed by averaging counts for four fields of each specimen from duplicate samples of at least three independent experiments.

**Results**

*Rosiglitazone reduced endotoxin induced cytokine secretion*

The changes in inflammatory cytokines expression due to endotoxin exposure were quantified by ELISA. Exposure to endotoxin upregulated the secretion of inflammatory cytokines. The explants from the LPS group had significantly elevated levels of TNF-α (≥ 3.0 fold, p=0.034), RANTES (≥2.7 fold p=0.013), IL-8 (≥ 1.4 fold, p=0.034) and IL-1β (≥ 2.0 fold, p=0.042) when compared to the PBS treated control explants (Figure 12 A-D). Rosiglitazone treatment reduced this secretion and explants from the LPS+Rosi group had significantly reduced secretion of TNF-α (p=0.009), RANTES (p=0.0134), IL-8 (p=0.039) and IL-1β (p=0.016) when
compared to the LPS treated explants. LPS treatment significantly upregulated the expression of anti-inflammatory cytokine IL-10 ($\geq 1.8$ fold, $p=0.0005$) which was reduced by Rosiglitazone presence (LPS + Rosi group, $p=0.0007$) (Figure 12-E).

Figure 12: Rosiglitazone treatment reduced the inflammatory cytokine secretion in first trimester human placental explants. Cytokines secretion by first trimester human placental explants post 24hr LPS+/- Rosiglitazone treatment was assessed by ELISA. Rosiglitazone treatment significantly downregulated the secretion of inflammatory cytokines (A) TNF-$\alpha$, (B) RANTES, (C) IL-8, (D) IL-1$\beta$ and (E) IL-10. $n\geq12$, ‘*’ indicates significance at $p<0.05$ when compared to the LPS treated group.

**Rosiglitazone reduced endotoxin induced apoptosis and restored proliferation**

Pro-inflammatory cytokines have been shown to have effects on proliferation and cell
apoptosis in hematopoietic and mesangial cells (307, 308). To evaluate if endotoxin induced inflammatory cytokines had similar effects in trophoblast cells / placental tissue we assessed the rate of apoptosis – using a TUNEL assay. The endotoxin treated explants (LPS group) showed a significantly higher percentage of apoptotic trophoblast nuclei (>1.7 fold, p=0.02) when compared to the PBS treated control explants. The percentage of apoptotic nuclei in explants treated with LPS + Rosi was significantly lower when compared to the only endotoxin/LPS group (p=0.03) and comparable to the PBS control group (Figure 13A). The percentage of apoptotic nuclei between the Rosi and PBS control groups was not significantly different (Figure 13A).

**Figure 13:** Rosiglitazone treatment reduced endotoxin induced apoptosis and increased proliferation. (A) Percentage of apoptotic trophoblast cells identified by TUNEL staining and (B) Percentage of proliferating trophoblast nuclei after 24 hrs of treatment. (C) Representative images for positive PCNA staining across the 4 treatment groups, positive nuclei identified by brown color due to oxidation of DAB (black arrowheads). Inset shows the IgG control n= 4 - 8, ‘*’ indicates significance at p<0.05 when compared to the PBS control group, ‘#’ indicates significance at p<0.05 when compared to the LPS treated group. Scale bar: 50µm.

The rate of proliferation in treated tissues was assessed by counting the trophoblast nuclei
stained positive for PCNA antigen over the total number of nuclei. PCNA is an auxiliary protein involved in DNA replication and used as a marker for cell proliferation (309). The explants treated with endotoxin (LPS group) had significantly lower number of positively stained trophoblast nuclei (lowered to \( \leq 50\% \), \( p=0.01 \)) when compared to the PBS control group. Treatment with Rosiglitazone increased the rate of proliferation when compared to both the endotoxin treated explants and PBS control explants. The values reached statistical significance for the comparison between LPS and LPS + Rosi groups (\( p=0.02 \)) (Figure 13B and C). The rate of proliferation between the Rosi and PBS control groups was comparable (Figure 13B and C).

**Rosiglitazone reversed endotoxin mediated reduction in trophoblast differentiation marker expression**

To assess the effects of endotoxin on trophoblast differentiation, we assessed the expression of GCM1 and CG-\( \beta \) – both have been shown to be crucial for trophoblast differentiation (78, 310). Exposure to endotoxin significantly reduced the expression of both \( Gcm1 \) mRNA (~40% reduction, \( p=0.04 \)) as assessed by qPCR and protein (~30% reduction, \( p=0.01 \)) as assessed by western blotting (Figure 14A, B). Activation of PPAR\( \gamma \) via Rosiglitazone reversed this reduction and significantly induced expression of GCM1 at both mRNA (\( p=0.01 \)) and protein levels (\( p=0.05 \)) (Figure 12A, B).

For CG-\( \beta \), the endotoxin mediated downregulation was not significant on the mRNA level (~40% reduction, \( p=0.06 \)), but achieved significance at the protein levels secreted in the media (~40% reduction, \( p=0.009 \)) as quantified by ELISA (Figure 14C, D). PPAR\( \gamma \) activation did not significantly upregulate mRNA expression of CG-\( \beta \), however, secretion of CG-\( \beta \) (\( \geq 2.5 \) fold over LPS group, \( p=0.002 \)) in the media was significantly upregulated (Figure 14C, D). Interestingly, treatment with Rosiglitazone (Rosi group) also significantly induced protein expression of both GCM1 (1.3 fold over PBS controls, \( p=0.03 \)) and CG-\( \beta \) (1.6 fold over PBS
controls, p=0.002) (Figure 14A - D).

**Figure 14: Rosiglitazone reversed endotoxin mediated reduction in trophoblast differentiation marker expression.** Expression of trophoblast differentiation markers GCM1 and CG-β was assessed at mRNA level by qPCR (A, C) and protein level using ELISA and western blotting (B, D). Endotoxin exposure downregulated expression of both mRNA and protein levels of GCM1 and CG-β which were induced by Rosiglitazone treatment. n= 4 -8, ‘*’ indicates significance at p<0.05 when compared to the PBS control group, ‘#’ indicates significance at p<0.05 when compared to the LPS treated group.

**Rosiglitazone reduced endotoxin induced trophoblast invasion to control levels**

To determine the effects on trophoblast function, we assessed the effects of endotoxin exposure on trophoblast invasion in 1st trimester placental explants. Villous clusters with EVT tips were cultured on matrigel at 3% O_2, treated and the length of outgrowth monitored and quantified as described in the Methods section.

Endotoxin exposure induced invasion and the length of outgrowth into the matrigel 2.0 ± 0.4 (Mean ± SD) was significantly higher when compared to the control group: 0.9 ± 0.2 (p=0.0007) (Figure 15A, B). In the presence of Rosiglitazone (LPS + Rosi group), the outgrowth
length in was maintained at a mean length: $1.0 \pm 0.4$, comparable to that of the control group.

The mean outgrowth length in Rosi group was similar to the control group: $0.99 \pm 0.2$.

![Figure 15: Endotoxin increased invasion in 1st trimester human placenta after 24 hrs of treatment.](image)

Villous clusters with EVT tips were cultured on matrigel and treated for a period of 48 hrs. (A) Representative images for mean length of invasion over the culture period. (B) Graph shows mean length of invasion in different groups measured after 24 hrs of treatment. n= 3, ‘*’ indicates significance at p<0.05 when compared to the PBS control group, ‘#’ indicates significance at p<0.05 when compared to the LPS treated group. Magnification: x100

**Endotoxin exposure increased invasion in the trophoblast cell line HTR-8/SV neo**

Endotoxin mediated increase in the length of trophoblast outgrowths observed in the treated explants was counterintuitive due to the decrease in expression of trophoblast
differentiation markers. Gestational age and oxygen concentration have been shown to play a critical role in trophoblast invasion (311) in 1st trimester placenta. To validate our observations on endotoxin mediated effects on invasion are independent of O2 levels and gestational age, we used the trophoblast cell line HTR-8/SV neo.

Similar to the observations in explants, exposure to endotoxin significantly increased the number of HTR-8/SV Neo cells (12,974± 3128 (Mean± SD), p=0.01) invading into the matrigel, when compared to the PBS control group (5560 ± 3221) (Figure 14A, B). Presence of Rosiglitazone in the culture significantly lowered these numbers (L+R group: 7819 ± 1607, p=0.05) when compared to the LPS group (Figure 16A, B). The number of invading cells was comparable in the PBS, Rosi only and LPS+ Rosi groups.

Figure 16: Rosiglitazone reduced endotoxin induced invasion in trophoblast cell line HTR- 8/SV Neo. Graph shows the average number of cells counted in the lower chamber in the matrigel invasion assay with HTR-8/SV Neo cells. Treatment with LPS significantly increased number of cells in the lower chamber which reduced when treated with Rosiglitazone. (B) Representative images shows cells in the lower chamber in wells with respectively labelled treatments. n=6, * indicates significance at p<0.05 when compared to the PBS control group, '#' indicates significance at p<0.05 when compared to the LPS treated group. Scale bar: 50µm
Endotoxin exposure induced integrins switching in HTR-8/SV neo cells

Integrin switching is a physiological event during trophoblast invasion (312). The expression of integrin α1 expression is upregulated in differentiating and invasive trophoblast cells whereas, integrin α6 expression is restricted to noninvasive cytotrophoblasts (312). To further validate the effects on trophoblast invasion, the HTR-8/SV neo cells were stained with antibodies against integrins α1 and α6 (Figure 16C) and the staining intensity quantified.

HTR-8/SV neo cells treated with endotoxin had a significantly higher expression of integrin α1 (LPS v/s PBS: 29.4±1.6 v/s 8.3±1.4 arbitrary units (AU), (Mean ± SD), p<0.0001) and reduced expression of integrin α6 (LPS v/s PBS: 10.4±2.0 v/s 38.3±1.9 AU, p<0.0001) when compared to the PBS controls (Figure 16D). Treatment with Rosiglitazone, prevented this switch and the LPS + Rosi group had significantly lower expression of integrin α1 (LPS + R v/s LPS: 8.6±1.9 v/s 29.4±1.6 AU, p<0.0001) and higher expression of α6 (LPS + R v/s LPS: 33.1±1.5 v/s 10.4±2.0 AU, p<0.0001) when compared to the LPS treated group. The expression of both integrin α1 and α6 in the LPS + Rosi, Rosi and PBS groups were comparable (Figure 16C and D). Additionally, we also assessed α1 and α6 staining intensity in cells treated with endotoxin and NF-κB inhibitor. Treatment with NF-κB inhibitor prevented the integrin switching in response to LPS exposure. The staining intensity of α1 in the LPS + NF-κB inhibitor group was significantly lower (LPS + NF-κB inhibitor v/s LPS: 10.3 ± 2.4 v/s 29.4±1.6 AU, p<0.0001), and α6 was significantly higher as compared to the LPS group (LPS + NF-κB inhibitor v/s LPS: 48.7 ± 3.4 v/s 10.4±2.0 AU, p<0.0001)

Discussion

Inflammation and trophoblast differentiation are complementary processes that ensure successful placentation and pregnancy maintenance. The cytokines and growth factors secreted
by both the immune cells and trophoblast cells at the maternal fetal interface control the proliferative and invasive capacity of trophoblasts (19, 277). The trophoblast cells in turn engage in processes like selective expression of cell surface receptors and regulation of local immune cell activation that protect the fetus from rejection (130, 275, 276). Failure to do so has been associated with a wide spectrum of pregnancy related disorders (289, 290, 296).

Several studies have evaluated the molecular pathways involved in the inflammatory response of the trophoblast cells in response to infection and/or inflammatory stimuli (288, 302). However, the effects of inflammation on trophoblast differentiation have not been assessed in great detail. Studying the effects of inflammation on trophoblast differentiation will help to better understand disorders such as PE, IUGR and PTB. All of the latter are known to be associated with increased inflammation and abnormal trophoblast differentiation (293, 294, 313).

A protein involved in trophoblast differentiation is the transcription factor PPARγ (150, 185). Interestingly, PPARγ also has a known anti-inflammatory action and its activation was recently shown prevents PTB and reduces inflammation in the mouse model of endotoxin induced PTB. However its anti-inflammatory role in 1st trimester human placenta has not been explored. In the current study we assessed the effects of LPS on trophoblast inflammatory response and differentiation and the potential role of PPARγ activation in reversing these effects.

Here, exposure of 1st trimester placental explants to LPS (1µg/ml) for 24 hrs significantly induced the secretion of inflammatory cytokines - TNF-α, IL-1β, IL-8, and RANTES - similar to the observations made in other cell culture models (288, 302). Additionally, we observed a significant increase in secretion of the anti-inflammatory cytokine IL-10 post endotoxin exposure. LPS mediated induction in IL-10 expression was shown in human alveolar macrophages, kupffer cells and blood monocytes (314, 315). Gniesinger et al reported a similar
induction of IL-10 in primary trophoblasts isolated from term placentas (316). Upregulation of IL-10 secretion in response to endotoxin is interpreted as a defense mechanism against the ensuing inflammatory damage (317-321). We suggest a similar mechanism for IL-10 upregulation in our study. Activation of PPARγ via Rosiglitazone significantly reduced the secretion of TNF-α, IL-1β, IL-8, and RANTES - cytokines (Figure 12 A-D) including IL-10, confirming its anti-inflammatory action in 1st trimester human placenta.

PPARγ activation by Rosiglitazone has been reported to exert its anti-inflammatory action via transrepression NF-kB activity in several non-pregnancy related animal and human models of diseases (146, 199, 212). Our group recently validated the anti-inflammatory action of PPARγ at systemic and local levels by repressing NF-κB activity in a mouse model of PTB (235, 304). In the current study, we observed a significant reduction in TNF-α and RANTES - specific targets of the NF-κB pathway (Figure 12 A, D). Based on the evidence present in literature and our previous observations, we speculate a similar mechanism to be present in the human first trimester placenta.

We further studied the effects of endotoxin exposure on apoptosis and proliferation specifically on the trophoblast cells in cultured explants. LPS exposure has been shown to induce apoptosis and reduce proliferation in immune cells (322). Studies with LPS and isolated primary trophoblast cells reported increase in apoptosis post three days of exposure and no effects on proliferation (288, 323). Exposure to high concentrations of recombinant inflammatory proteins - TNF-α and IFN-γ - was however reported to increase apoptosis and block proliferation in trophoblast cell line JEG-3, whereas IL-8 exposure was shown to increase proliferation in HTR-8SV/Neo cells (297, 324, 325). In our studies, we observed a significant increase in apoptosis and reduction in proliferation in trophoblast cells post 24 hrs of endotoxin
exposure suggesting a negative effect on cell viability (Figure 13). In the explants treated with LPS + Rosiglitazone, both apoptosis and proliferation rates were restored to control levels (Figuere 13 A-D). Further, the levels of both apoptosis and proliferation in the explants from the Rosi only group were comparable to the PBS treated controls (Figure 13 A, C). These results suggest that in the placenta, PPARγ mediates the effects on trophoblast apoptosis and proliferation indirectly, possibly via a downregulation of the inflammation cascade.

The proliferative capacity in the trophoblast cells is coupled to differentiation with reduction in proliferation as cells differentiate (326). To determine if the reduction in proliferation observed in our study affected trophoblast differentiation, we assayed the expression of Glial cell missing 1 (GCM1) and chorionic gonadotropin – beta (CG-β) as proxies for this process. GCM1 is a transcription factor reported to be crucial for terminal differentiation of trophoblast cells and consequently for maintaining a balance between trophoblast proliferation and differentiation (78). CG-β is a glycoprotein hormone secreted by and involved in differentiation of trophoblast cells (310, 327). Contrary to our expectations, exposure to endotoxin significantly downregulated expression of both GCM1 and CG-β (Figure 14A-D). Treatment with Rosiglitazone stimulated expression of both proteins and expression in LPS + Rosi group was significantly higher over the endotoxin treated group. The expression of GCM1 and CG-β in the Rosi only group was also significantly higher over the PBS treated control. PPARγ mediated upregulation in GCM1 was previously reported by our group in the BeWo trophoblast cell line, whereas upregulation in CG-β was reported by us as well as other groups (69, 150). Endotoxin mediated downregulation in GCM1 protein has never been reported and expression of CG-β was shown to be unaffected (328). Further, since PPARγ activation upregulated the expression of both targets irrespective of the endotoxin mediated
downregulation, we suggest that LPS and PPARγ regulate expression of GCM1 and CG-β by independent mechanisms. Interestingly, decreased placental expression of GCM1 and lower CG-β levels were reported in pre-eclamptic women (77, 329). Endotoxin mediated decrease in GCM1 and CG-β observed in our study might explain the relationship between increased inflammation and lowered differentiation marker expression observed in PE.

Both GCM1 and CG-β have been shown to affect trophoblast function - specifically trophoblast invasion capacity (78, 327). GCM1 knockdown in 1st trimester human explants significantly inhibited invasion (78). Whereas contradictory results have been reported for the effect of CG-β on trophoblast invasion by other groups. It was reported to increase invasion in the trophoblast cell line JEG-3 whereas higher concentrations were shown to reduce invasion in isolated primary trophoblast cells (327, 330). More recently, Prast et al reported that CG-β stimulated trophoblast invasion in a culture system similar to ours (331). As endotoxin exposure affected both GCM1 and CG-β expression in our study, we evaluated if this reduction resulted in any perturbations in trophoblast invasion. Surprisingly, we observed that endotoxin treated explants displayed significantly higher invasion capacity (longer mean outgrowth length) when compared to the PBS treated controls. This was restricted to control levels in explants treated with Rosiglitazone (LPS + Rosi group). Mean invasion length in explants from the Rosi only group was also comparable to the PBS control group. Previous studies evaluating effects of endotoxin on invasion have reported a decrease in invasion in isolated primary trophoblast cell model (288, 302). While the contrasting results may be attributed to differences in cell models used for the studies, we asked if these discrepancies were due to differences in gestational age of the tissue and the O2 tension used for the matrigel invasion experiments. The experimental setup for the invasion assay was different from the one used for previously discussed experiments in
two ways: (i) it used early first trimester tissue (5-7 weeks v/s the 10-12 weeks of gestation age), as at an older gestation age the (invading EVT cells are rare and) invasion capacity is potentially reduced (ii) it used a lower O$_2$ tension (3% v/s the 8%) as it is considered to be more reflective of the physiological O$_2$ concentration at 5-7 weeks of gestation (332). Both these factors have been shown to impact trophoblast cell invasion (311, 333, 334). To confirm our observations on endotoxin mediated effects on trophoblast invasion are independent of age and O$_2$ tension, we repeated the matrigel invasion assay using the HTR-8/SV neo trophoblast cell line. Similar to the effects observed in placental explants, exposure to endotoxin significantly induced invasion in HTR-8/SV neo cells, which was reduced to control levels when treated with Rosiglitazone (LPS+ Rosi, Rosi group) (Figure 16). To further validate our results and confirm induction of an invasive phenotype, we performed immunostaining for the integrins α1, α6 and quantified their expression in HTR-8/SV neo cells. Trophoblast cells undergoing differentiation towards the invasive phenotype have been shown to temporally and spatially switch their cell surface integrin expression from integrin α6 to integrin α1 (312). We observed that the changes in α1 and α6 expression were in accordance with our invasion results. Endotoxin exposure caused the HTR-8/SV neo cells to significantly upregulate α1 expression while simultaneously downregulating α6 compared to the controls (Figure 17). Rosiglitazone treatment prevented this switch and expression levels in the LPS + Rosi and Rosi groups were comparable to the ones in PBS treated control groups i.e.significantly low α1 and high α6 expression. Previous reports assessing the effects of PPARγ activation on trophoblast cells invasion have reported negative effects of the transcription factor (335-337). However, these studies were performed in isolated primary trophoblasts cells cultured at 5% O$_2$ tension. We suggest that differences in the cell model and culture conditions might be the confounding factors for the contrasting observations made in the
current study. Also, since Rosiglitazone treatment alone did not inhibit/reduce invasion, we concluded that the inhibitory activity of PPARγ does not directly affect trophoblast invasion and acts via regulation of inflammatory pathways triggered by LPS.

**Figure 17**: Rosiglitazone prevented endotoxin mediated integrin switching in trophoblast cell line HTR-8/SV Neo. HTR-8/SV Neo cells were stained for assessing the expression of integrins α1 and α6. (A) Graph shows mean staining intensity for α1 and α6 across groups. (B) Representative images showing α1 and α6 integrin staining across different treatments, showing the integrin switch in the LPS group which was prevented in the LPS + Rosi and LPS+ NF-κB inhibitor group. n=6, *'*, 'ψ' indicates significance at p<0.05 when compared to the PBS control group for α1 and α6 respectively, '#', ‘¥’ indicates significance at p<0.05 when compared to the LPS treated group for α1 and α6 respectively. Scale bar: 50µm.

The inflammatory action of LPS is triggered by binding to its specific receptor Toll like receptor – 4 (TLR4) and downstream activation of the inflammatory transcription factor NF-κB (338, 339). To determine if the effects on trophoblast invasion were mediated via this
pathway, we treated HTR cells with LPS +/- TPCA, a specific inhibitor of NF-κB activity and assessed for induction of invasive phenotype. We observed that in presence of NF-κB inhibitor, the trophoblast cells failed to switch integrin subtype (Figure 17) suggesting that the LPS driven differentiation towards the invasive phenotype is mediated by activation of NF-κB. We also qualitatively confirmed this pathway in our explant culture model by matrigel invasion assay. Additionally, Rosiglitazone via PPARγ activation has been shown to repress the NF-κB activity, which would further explain Rosilgitazone mediated reduction in trophoblast invasion post endotoxin treatment (100).

To summarize, in the current study we report that endotoxin exposure in 1st trimester human placenta (i) causes inflammatory cytokine expression, (ii) induces trophoblast cell apoptosis, (iii) reduces trophoblast cell proliferation, (iv) downregulates expression of trophoblast differentiation related proteins and (v) increases trophoblast invasion via activation of NF-κB. Activation of PPARγ via Rosiglitazone reduces the endotoxin mediated effects on inflammatory cytokine production, apoptosis, proliferation and invasion and further stimulates expression of trophoblast differentiation markers.

Limitations of Aim 2

The current study focusses on the inflammation mediated via activation of NF-κB and its effects on trophoblast function. LPS treatment has been shown to induce inflammation by activation of transcription factors such as STAT and AP-1 in addition to NF-κB (340, 341). Effects of inflammation due to activation of STAT and AP1 on trophoblast differentiation would further help in understanding the link between inflammation and placental function. The current study also outlines the anti-inflammatory action of PPARγ in the placenta and its role in reversing inflammation mediated effects on trophoblast differentiation. However, PPARγ has
been suggested to play a role in trophoblast differentiation beyond inflammation. Evaluating the molecular pathways governed by PPARγ in trophoblast lineages will further help in understanding its role in placental physiology and disease.
CHAPTER 5 - PPARγ REGULATES TROPHOBLAST DIFFERENTIATION VIA GLIAL CELL MISSING -1

Introduction

Peroxisome proliferator-activated receptor-gamma (PPARγ) belongs to the nuclear hormone receptor superfamily. Apart from being involved in lipid metabolism, like its other two subtypes PPARα and β, it was shown to be crucial for successful placentation. Barak et al. reported that PPARγ knockouts die in utero due to gross placental and cardiovascular abnormalities (178). Replenishing PPARγ expression in the extra-embryonic lineages of PPARγ null mutants resulted in viable pups suggesting a critical role of PPARγ in placental development (178). Further analysis of the PPARγ null embryos revealed that these placentas had a significantly thicker layer of undifferentiated trophoblast cells and an under-developed placental vasculature. These findings suggested a dysregulation of the trophoblast differentiation pathway mediated by PPARγ. Parast et al. using PPARγ−/− murine trophoblast stem cells that re-introducing PPARγ in these cells rescued differentiation of the syncytiotrophoblast and labyrinthine trophoblast – crucial components of mouse placental structure and vasculature - by upregulating the expression of Glial cell missing 1 (GCM1) (303). GCM1 is a transcription factor regulating differentiation of mouse and human trophoblast lineages (74). Functionally, the labyrinth trophoblast in the mouse placenta resembles the villous trophoblast in human placenta which also expresses GCM1 (76). Baczyk et al. reported that knockdown of GCM1 expression in 1st trimester human placenta altered trophoblast proliferation, syncytial fusion in villous trophoblast and inhibited invasion in extra-villous trophoblast cells – supporting its critical role in human trophoblast differentiation (78). Recently, Levytska et al. showed that activation of PPARγ in the human choriocarcinoma trophoblast cell line – BeWo significantly upregulated GCM1 expression (150). Further, our studies in 1st trimester human placenta also showed
upregulation in GCM1 and its downstream target CG-β on treatment with Rosiglitazone at both transcript and protein levels (Figure 14, Chapter 4). *In-silico* analysis of GCM1 promoter identified 2 putative PPARγ target sites 20bp and 211bp upstream of the transcription start site (Figure 19). Unpublished work from our laboratory using the electrophoretic mobility shift assay (EMSA) showed that PPARγ can bind to both these sites in the GCM1 promoter. For the current study, *we hypothesized that in human trophoblast cells PPARγ regulates GCM1 expression by binding to its specific target sites in the GCM1 promoter.*

**Materials and Methods**

**Cell culture and treatments**

The human choriocarcinoma cell line JEG-3 was cultured in Dulbecco's Modified Eagle Medium (DMEM) and Ham's F12 (1:1; DMEM/F12) media (Invitrogen, CA) containing 10% FBS and 1% Antibiotic-Antimycotic (Life Technologies, CA) in a humidified incubator at 5% CO₂. For the manipulation of PPARγ activity, the cells were treated in duplicates with a specific PPARγ antagonist SR-202 (TOCRIS, Bioscienc, UK) at 400μM concentration or the agonist Rosiglitazone at 50μM for 3hrs. At the end of 3hrs of incubation the cells from one replicate were lysed in Qiazol (Qiagen, Germany) for RNA extraction. The second replicate was used for chromatin immunoprecipitation to investigate the physical locations of the transcription factor. The experiment was repeated 4 times.

**Chromatin Immunoprecipitation**

After the respective treatments, the media was aspirated from the wells and cells were gently washed with 1ml ice cold PBS (Life Technologies, CA). The cells were then cross-linked by adding 4% formaldehyde solution (Thermo Scientific, MA) and placing on a shaker at RT for 6 mins. The crosslinking was stopped by adding 125mM glycine solution (Fisher
Scientific, MA) and cells were washed with 1 ml cold PBS for 5 mins to remove the residual formaldehyde. The cells were then lysed in cell lysis buffer (10mM HEPES, 60mM KCl, 1mM EDTA, 1mM 1,4-dithiothreitol, 1mM PMSF, 0.075% NP-40, pH 7.6) for 3 mins and spun at 1500 rpm for 4 mins. The pellet was re-suspended in nuclei lysis buffer (10mM EDTA, 50mM Tris HCl, 1% SDS, pH 8.1) and incubated on ice for 30 mins to obtain chromatin. The resulting chromatin lysate was then sonicated on a focused ultra-sonicator (S220, Covaris, MA) to obtain fragments between 200-500bp. Post-sonication, the amount of DNA was directly quantified in the sonicated chromatin using a spectrophotometer (NanoDrop). For each treatment immunoprecipitation reactions were set up using anti- RNA Pol II CTD and anti- PPARγ antibodies (Thermo Scientific, MA) and an aliquot was saved as input fraction. Each immunoprecipitation reaction contained ~5µg chromatin, 4µg respective antibody and 9µL Dynabeads Protein G magnetic beads (Invitrogen, MA) and was rotated overnight at 4°C. On the second day, the beads were washed by rotating for 5 mins at 4°C. The bound DNA was eluted by adding 40µL Chelex beads (Bio-Rad Laboratories, CA) and heating at 100°C for 10 mins followed by reverse crosslinking by adding 2µL Proteinase K and incubating at 55°C for 60 mins and RNase treatment for 30 mins at 37°C. 3µL of the eluted DNA was used for qPCR analysis using the primer pairs: 5’ -- CCAGGC TGCTCTTACCTATCC --- 3’ & 5’-- TCTTACTGCTGGTTCAAGTCCC -- 3’ for site I and 5’-- CTACTGTGAATCGTCTGCCT -- 3’ and 5’—TCTTCCAGAATGCCAGCAA -- 3’ for site 2 spanning the two PPARγ target sites in the GCM1 promoter. The enrichment of the GCM1 promoter was calculated using the percent input method outlined in (342).

**RNA extraction and qPCR analysis**

The cells were lysed in Qiagenol and RNA was extracted using RNeasy Plus Universal
Mini kit (Qiagen, Germany) as per the manufacturer’s protocol. The extracted RNA was quantified using Nanodrop and 1µg was reverse transcribed using iScript RT synthesis kit (Bio-Rad Laboratories, CA). Real-time PCR was performed on the Bio-Rad CFX384 real time system in triplicates in 10uL total reaction volume containing 10 ng of template cDNA, 5µL of SYBR-green master mix (LuminoCT, Sigma-Aldrich, MO) and 500nM of primers. The primers used for assessing the expression levels of target and housekeeping genes are outlined in Table 5. Data was analyzed using the delta delta CT method as described in (251).

Table 5: Primer sequences used for gene expression analysis in JEG-3 cells.

<table>
<thead>
<tr>
<th>Gene Name</th>
<th>Gene Symbol</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytochrome - C 1</td>
<td>Cyc1</td>
<td>5′-CAT CAT CAA CAT CTT GAG CC-3′</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5′-CAG ATA GCC AAG GAT GTG TG-3′</td>
</tr>
<tr>
<td>Tyrosine 3-monooxygenase</td>
<td>Ywh</td>
<td>5′- CGG CCA GGA CAA ACC AGT AT -3’</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5′- ACT TTT GGT ACA TTG TGG CTT CAA -3’</td>
</tr>
<tr>
<td>TATA Box Binding Protein</td>
<td>Tbp</td>
<td>5′- CAC ATC ACA GCT CCC CAC CA-3’</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5′- TGC ACA GGA GCC AAG AGT GAA-3’</td>
</tr>
<tr>
<td>Glial cell missing 1</td>
<td>Gcm1</td>
<td>5′- TGA ACA CAG CAC TTT CCT CCA GAT-3’</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5′- CCA CTG TAA CTA CCA GGC AAT-3’</td>
</tr>
</tbody>
</table>

Results

Gcm1 expression is differentially regulated by PPARγ agonist and antagonist

Similar to the observation reported by Levytska et al. Rosiglitazone treatment significantly induced Gcm1 mRNA expression in JEG-3 cells (3.7 fold, p=0.01) when compared to the untreated controls (150). Cells treated with the PPARγ antagonist SR202, had significantly lower Gcm1 expression (1.4 fold, p= 0.05) as compared to the Rosiglitazone treatment. The expression of Gcm1 was comparable between the untreated control cells and SR202 treated cells (Figure 18).

Figure 18: Gcm1 expression correlates to PPARγ activation status. Treatment with PPARγ agonist Rosiglitazone significantly upregulated the expression of Gcm1, whereas treatment with the antagonist significantly reduced Gcm1 expression. N=4, *: Significant V/s control at p<0.05, #: Significant v/s Rosiglitazone at p<0.05
**PPARγ and active RNA polymerase II preferentially bind to Site I in the GCM1 promoter to regulates its expression**

The binding of transcription factors PPARγ and active RNA Pol II to the GCM1 promoter was evaluated by performing chromatin immunoprecipitation assay. We observed that both RNA Pol II and PPARγ precipitates were positively enriched for both target sites, I and II. Treatment with Rosiglitazone resulted in higher enrichment of the site I (2.7 ± 1.1 (Mean fold change ± SD), p=0.02) when compared to its enrichment in untreated controls. The enrichment for target site II located -211bp for immunoprecipitation with PPARγ antibody was 1.5 ± 0.62, but did not reach statistical significance Figure 19 & 20A). For immunoprecipitation with RNA Pol II, the enrichment for site I was 2.2 ± 1.2 (p=0.028) and site II was 1.5 ± 0.3 when compared to the enrichment of respective sites in untreated controls.

![Figure 19: Illustration for putative PPARγ binding sites in GCM1 promoter.](image)

Further, we also observed that PPARγ binding to the site I correlated to its activation status. Treatment with Rosiglitazone significantly increased the enrichment of the binding site I (2.71 ± 1.1, p=0.02) when compared to the untreated controls. The enrichment of site I in the antagonist treated cells was lower (0.39 ± 0.2, p=0.026) when compared to the untreated controls, however the values did not reach statistical significance (Figure 20B).
Figure 20: PPARγ activation led to preferential binding and enrichment of the binding site I in GCM1 promoter. (A) PCR analysis of PPARγ and Pol II immunoprecipitants showing significantly higher enrichment of the binding site I when compared to the untreated controls. (B) Treatment with Rosiglitazone significantly increased the enrichment of binding site I, which reduced significantly after treatment with the antagonist SR202. N=4, *: Significant V/s control at p<0.05, #: Significant v/s Rosiglitazone at p<0.05

Discussion

PPARγ mediated upregulation of GCM1 expression was previously reported by Levytska et al. in the BeWo choriocarcinoma cell line (150). Our studies in 1st trimester villous explants showed a similar upregulation (Chapter 4, Figure 14A, B). In silico analysis revealed two putative PPARγ binding sites in the GCM1 promoter. In this study, we aimed to extend our previous observations by showing that PPARγ increases Gcm1 expression by direct binding to its target sites in the GCM1 promoter region. We performed chromatin immunoprecipitation with PPARγ and active RNA Pol II antibodies to evaluate if (i) PPARγ physically binds to these target sites and (ii) PPARγ binding recruit’s RNA Pol II to the target sites for transcription.

The JEG-3 cells were treated with PPARγ agonist – Rosiglitazone and antagonist – SR202 for 3 hrs. Successful modulation of PPARγ activity post agonist/antagonist treatment was validated by assessing the expression of known PPARγ target gene Fabp4. Like the observations made by Levytska et al, treatment with Rosiglitazone significantly upregulated Gcm1 expression confirming changes in PPARγ activity due to agonist treatments in our
experimental set up (Figure 18). The chromatin immunoprecipitation assay further showed that PPARɣ and RNA Pol II bound to both target sites I and II in the GCM1 promoter however, post Rosiglitazone treatment the enrichment for site I was significantly higher compared to site II. This suggested that PPARɣ activation causes preferential binding of PPARɣ and recruitment of RNA Pol II to target site I. This also correlated with the increase in \textit{Gcm1} expression observed in Figure 18. We also observed that treatment with PPARɣ antagonist SR202 significantly reduced enrichment of binding site I. However, we observed that the decreased in PPARɣ activity did not reduce the expression of \textit{Gcm1} suggesting that in JEG-3 cells, the basal expression of \textit{Gcm1} may be regulated by factors other than PPARɣ. Further, these observations were also contrary to the observations made by Levytska et al. in BeWo choriocarcinoma cell line further suggesting that trophoblast cell lines might differ in regulation of \textit{Gcm1} expression and that results obtained should be interpreted with caution.

Based on previous data and the current study we report that upon activation, PPARɣ regulates GCM1 expression by preferentially binding to the specific target site I (-21bp upstream of transcription start site) in the GCM1 promoter in JEG-3 cells. Also, in combination with the data obtained by Levytska \textit{et al} our data highlights the need for caution while interpreting molecular data from cancerous cell lines and calls for development of better models to study trophoblast differentiation.
CHAPTER 6 - DEVELOPMENT OF A CULTURE MODEL FOR SIMULTANEOUSLY STUDYING PPARγ MEDIATED REGULATION IN EXTRA-VILLOUS AND VILLOUS TROPHOBLAST LINEAGE DIFFERENTIATION

Introduction

Abnormal trophoblast differentiation has been associated with pathologies like PE – affecting 5-8% pregnancies, IUGR – affecting 4-7% pregnancies, GDM – affecting 2-5% pregnancies and PTB – that accounted for 9.5% live births in 2015 (61, 62, 343, 344). Understanding the molecular basics of placental development and function could provide insights into the etiologies of these disorders. Interestingly, abnormal expression of PPARγ has also been reported in cases of IUGR with PE and IUGR (103, 104). PPARγ expression was reported to be unaltered in women with PE however significantly lower levels of PPARγ activators were reported in their serum (103, 105). These studies highlight a crucial role for PPARγ activity in placental pathologies. However, we still lack an understanding of the molecular pathways regulated by PPARγ in human placenta.

In-vitro studies focusing on PPARγ activity in isolated 1st trimester human EVT’s showed that treatment with PPARγ agonists reduced invasion, suggesting its negative involvement in differentiation towards the EVT lineage (335, 337). However, a similar study with isolated villous trophoblast showed induction of differentiation on treatment with agonists (66). Handschuh et al. showed that PPARγ activation had opposite effects on human chorionic gonadotropin (hCG) subunit expression patterns in the villous and extra-villous trophoblast (336). hCG is a critical hormone shown to be involved in proliferation and differentiation processes in both trophoblast lineages (310, 330). Differential regulation of hCG by PPARγ suggests specialized role for the receptor in each lineage. The current study aimed to explore the differential role of PPARγ in VT and EVT lineages. A critical limitation for this aim was availability of a suitable culture model. Most studies evaluating the role of PPARγ in trophoblast
cells, rely on the use isolated primary trophoblast cells. Primary cell models, although generally helpful, have the common obstacle that they lack tissue integrity and tend to spontaneously differentiate (345, 346). We therefore aimed to develop a culture model using 1st trimester placental explants that would enable simultaneous assessment of both lineages. The data shown here outlines our preliminary work in which we (i) established the culture and treatment conditions to ensure maintenance of tissue viability (ii) confirmed the purity of isolated EVT fractions by assessing expression of specific markers - Platelet And Endothelial Cell Adhesion Molecule 1 (PECAM 1) and Human Leukocyte Antigen-G (HLA-G).

**Materials and Methods**

**Tissue collection**

Human first trimester placental tissues (5-7 weeks) were obtained with written informed consent from healthy pregnant women following elective termination of pregnancy at the Michigan Family planning facility, Michigan, US and Morgentaler Clinic, Toronto, Canada. The Institutional Review Board (IRB) of Wayne State University and Mount Sinai Hospital (MSH) Research Ethics Board approved all consent forms and protocols used in this study.

**Placental explant culture**

Individual clusters of 5-7 week villi were dissected under a stereomicroscope and verified for the presence of extra-villous trophoblasts (EVT’s) on the villous tips. These clusters were cultured on Millicell-CM inserts (12-mm diameter, 0.4-μm pores; EMD Millipore, MA) pre-coated with 0.2 mL of undiluted growth factor phenol red -free Matrigel (Corning, MI). The matrigel containing inserts were placed in a 24-well culture plate. The bottom chamber was filled with 300μL DMEM/F12 (Life Technologies, CA) medium supplemented with 10% Fetal bovine serum (Atlanta Biologicals) and 1% Anti-Anti (Life Technologies, CA). The upper
chamber contained 200μL of the same medium. The explants were treated in duplicates by supplementing the media with either 10μM Rosiglitazone (Selleckchem, MA) or 1μM of T0070907. The explants were cultured at 3% O2, 37°C for a total of 72 hrs. Explants that did not show visible outgrowth in the first 24 hrs were discarded. The culture media was replaced with fresh media (with respective treatments) every 24 hrs. The explants were imaged every 24 hrs to record the outgrowth using Hamamatsu Digital camera and the outgrowths were measured using the ImageJ software. Each treatment was performed in duplicates for every tissue and the entire experiment was conducted thrice. At the end of 72 hrs, one replicate was processed for RNA extraction and the other for immunohistochemistry.

*Tissue dissection, RNA extraction and qPCR analysis*

To dissect the explants for RNA extraction, media from both the lower chamber and Millicell-CM inserts was aspirated. The inserts were taken and the lower membrane holding the matrigel was carefully separated. The matrigel with the explants was then taken out and dissected under a stereomicroscope as outlined in Figure 21. The non-invaded part of the explant was considered as enriched VT fraction whereas the invaded part was collected as enriched EVT fraction. Both the VT and EVT fractions were lysed in Qiazol and processed for RNA extraction.

The explants/cells were lysed in 0.9 ml Qiazol (Qiagen, Germany). Total RNA was extracted (RNeasy Plus Universal Mini kit, Qiagen, Germany) and all samples were reverse transcribed simultaneously using the RT synthesis kit from Bio-Rad per the manufacturer’s protocol (iScript Reverse Transcription Supermix, Bio-Rad Laboratories, CA). Real-time PCR was performed on the Bio-Rad CFX384 real time system in triplicates in 10uL total reaction volume containing 5 ng of template cDNA, 5μL of SYBR-green master mix (LuminoCT, Sigma-
Aldrich, MO) and 500nM of primers. The primers used for assessing the expression levels of target and housekeeping genes are outlined in Table 6. Data was analyzed using the delta CT method as described in Drewlo 2011.

Table 6: List of primer sequences for gene expression analysis in invaded and floating villous trophoblast

<table>
<thead>
<tr>
<th>Gene Name</th>
<th>Gene Symbol</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytochrome - C 1</td>
<td>Cyc1</td>
<td>5'-CAT CAT CAA CAT CTT GAG CC-3'</td>
</tr>
<tr>
<td>Tyrosine 3-monooxygenase</td>
<td>Ywh</td>
<td>5'-CAC ATC ACA GCT CCC CAC CA-3'</td>
</tr>
<tr>
<td>TATA Box Binding Protein</td>
<td>Tbp</td>
<td>5'-CAC ACA GCT CCC CAC CA-3'</td>
</tr>
<tr>
<td>Human Leukocyte Antigen-G</td>
<td>Hla-G</td>
<td>5'-CAC ACA GCT CCC CAC CA-3'</td>
</tr>
<tr>
<td>Platelet And Endothelial Cell Adhesion Molecule 1</td>
<td>Pecam 1</td>
<td>5'-ACT TTT GGT ACA TTG TGG CTT CAA -3'</td>
</tr>
</tbody>
</table>

**Immunohistochemistry**

The explants were fixed (with the matrigel) by adding 4% paraformaldehyde for 10 mins. The explants were then dehydrated and paraffin embedded, sectioned at 5µm thickness and mounted onto glass slides. For immunostaining, the sections were rehydrated and deparaffinized, followed by antigen retrieval using Dako Target retrieval solution (Agilent, Dako, CA). The intrinsic peroxidase activity was then quenched by incubating the sections with 3% peroxide (Fischer Scientific, MA) for 30 mins at RT, followed by 1 wash with 1X PBS. The
sections were then incubated overnight at 4°C with anti-Ki67 antibody (Santa Cruz TX), and 10μg/ml nonimmune Rabbit IgG (Jackson Immunoresearch, PA) (used as a negative control). On the next day, the slides were washed 3 times with 1X PBS containing 0.1% Tween 20 (5 minutes/wash). Then the slides were incubated with a peroxidase-conjugated polymer coupled to anti-rabbit IgG (EnVision Systems Peroxidase, Agilent, DAKO, CA) for 30 min. The peroxidase was visualized with a 1:1000 dilution of 3,3-diaminobenzidine (DAB, Agilent, DAKO, CA) in hydrogen peroxide for 3 min. The tissue was counterstained with hematoxylin, dehydrated and cover slipped. The staining was visualized using Nikon Eclipse 90i epifluorescence microscope (Nikon Inc, Japan).

**Results**

*Cultured explants contained proliferating cells and were viable at 72 hrs of culture*

We assessed the viability in the cultured explants by immunostaining for Ki67. The cells from both compartments, villous trophoblast (outside the matrigel) and extravillous trophoblast (invaded into the matrigel) stained positive for Ki67 indicating that the tissue still maintained proliferating cells (Figure 22).

*Figure 22: Immunohistochemistry for Ki-67 showed presence of proliferating cells in cultured explants. Representative image shows the VT and EVT structures in cultured explants. The explants stained positive for the proliferation marker Ki-67. ‘*’ stroma, ‘M’ matrigel.*
The isolated EVT fractions enriched for EVT-specific markers

We assessed the expression of EVT markers, Pecam1 and Hla-G in both our EVT and VT fractions. We observed that the EVT/matrigel fraction had significantly higher expression of both Pecam1 and Hla-g when compared to the villous/ floating fraction (Figure 23A & B).

![Figure 23: The extra-villous tissue fractions dissected out from matrigel inserts enriched for EVT markers. The graphs show expression of EVT markers (A) Pecam 1 and (B) Hla-g in villous (VT) and extra-villous fraction isolated from matrigel cultures. The expression of both markers is significantly higher in EVT fractions. N=, *: Significant V/s VT at p<0.05.](image)

PPARγ antagonist increased invasion

In preliminary experiments, we assessed the mean outgrowth length in the explants treated with PPARγ agonist (Rosiglitazone) and antagonist (T0070907). The outgrowth index was calculated by taking a ratio of the length of outgrowth after 24hr of treatment over the length before treatment for each explant. We observed that after 24hrs of treatment, the outgrowth index in Rosiglitazone treated explants was 1.1 ± 0.31 (Mean ± SD), similar to the 0.9 ± 0.3 in the control explants (Figure 24A and B). The outgrowth index in the T0070907 treated explants was higher (2.1 ± 1.4), however the values did not reach statistical significance.

Discussion

In the current study, we aimed to develop a culture model for simultaneous assessment of EVT and VT lineages. Currently used primary culture models suffer from the lack of tissue
integrity and spontaneous differentiation in culture conditions (346). Here we cultured early first trimester (5-7 weeks of gestational age) villous clusters with visible EVT’s at the tips on matrigel for 3 days. We observed that at the end of the culture period, the tissue still maintained its integrity and stained positive for proliferating cells marker Ki-67 (Figure 22). This suggests that the explants were still viable. We suggest a more comprehensive assessment such as analysis of apoptotic rate and estimating tissue necrosis would provide further insights into tissue viability.

A crucial step in the current study was to ensure the precise dissection of explant structures to obtain the VT and EVT’s with minimum cross-contamination. We assessed this by analyzing the mRNA expression of two EVT specific markers in both fractions – Pecam1 and Hla-g. We observed that both Pecam1 and Hla-g had significantly higher expression in the isolated EVT fraction when compared to the VT fraction. We suggest a similar analysis of the VT specific markers would further help ascertain the purity of isolated lineages. We also conducted preliminary experiments assessing the effects of PPARγ agonist and antagonist on outgrowth in
cultured explants. We observed that while PPARγ agonist did not significantly alter outgrowth, treatment with antagonist T0070907 increased it. Similar analysis in more explants would provide a concrete conclusion and more definitive answer for the effect of PPARγ on EVT outgrowth. Performing gene expression analysis of EVT and VT fractions isolated after agonist/antagonist treatments would further help in understanding role of PPARγ in differentiation of trophoblast lineages.

The current study thus provides the preliminary data towards establishment of a culture model for simultaneous assessment of EVT and VT lineages. Once completely established, the model can be used for assessment of molecular cross-talk and pathways involved in EVT/VT differentiation as well as placental development. Further, the model will also help in developing and screening therapeutics for intervention in placental dysfunction disorders.

**Limitations of Aim 3**

The current study provides proof for transcriptional regulation of GCM1 expression by PPARγ and suggests that PPARγ regulates trophoblast differentiation via GCM1. However further studies are needed to validate both these observations. Experiments involving site specific mutagenesis in GCM1 promoter would further verify the specificity of the PPARγ binding at the GCM1 promoter sites. And GCM1 knockdown experiments would reveal if the effects of PPARγ activation on trophoblast differentiation are GCM1 dependent. The current study also explored the role of PPARγ in trophoblast differentiation beyond regulation of GCM1 expression. It provided preliminary data for development of a unique culture model that would enable simultaneous assessment of PPARγ mediated regulation in EVT and VT lineages. Further development and analysis of the culture model is needed to validate its use for studying differentiation in trophoblast cell lineages.
APPENDIX A

IACUC Approval Letter

TO: Dr. Nardhy Gomez-Lopez
    OB/GYN
    275 E. Hancock

FROM: Lisa Anne Polin, Ph.D.
      Chairperson
      Institutional Animal Care and Use Committee

SUBJECT: Approval of Amendment # 3 to Protocol # A 07-03-15
         “Immunological mechanisms during term and preterm labor/birth”

DATE: September 1, 2015

The following requested changes to the above protocol have been reviewed and approved for immediate effect:

Request dated August 24, 2015:

To do further studies on preventative measures for preterm birth, since rosiglitazone, a PPARy agonist, suppresses the inflammatory signal transduction pathway initiated during preterm birth as described in the amendment request.

Mice, C57BL/6J, Females, 96, "D"
*To be purchased
Mice, C57BL/6J, Male and Female Offspring, 576, "D"
*Bred in house

This protocol, as amended, will be subject to annual review on the anniversary date of the initial IACUC review. This protocol was last reviewed on August 26, 2015.
APPENDIX B

IRB Approval Letter

NOTICE OF EXPEDITED APPROVAL

To: David Arman
Obstetrics/Gynecology
339 Mott Center

From: Sabrina Heidemann, M.D. or designee
Chairperson, Medical/Pediatric Institutional Review Board (MP4)

Date: August 03, 2015

RE: IRB #: 013515MP4E
Protocol Title: First Trimester Trophoblast Investigations
Funding Source: Sponsor: NATIONAL INSTITUTES OF HEALTH
Sponsor: KELLOGG FOUNDATION
Protocol #: 1501013712
Expiration Date: August 02, 2016
Risk Level / Category: Research not involving greater than minimal risk

The above-referenced protocol and items listed below (if applicable) were APPROVED following Expedited Review (Category (5)*) by the Chairperson/designee for the Wayne State University Institutional Review Board (MP4) for the period of 08/03/2015 through 08/02/2016. This approval does not replace any departmental or other approvals that may be required.

- Revised Protocol Summary Form (revision received in the IRB Office 7/24/2015)
- Protocol (received in the IRB Office 1/9/2015)
- Medical records are not being accessed for this study. Therefore, HIPAA does not apply.
- Research Informed Consent (revision dated 6/18/2015)

* Federal regulations require that all research be reviewed at least annually. You may receive a "Continuation Renewal Reminder" approximately two months prior to the expiration date; however, it is the Principal Investigator's responsibility to obtain review and continued approval before the expiration date. Data collected during a period of lapse approval is unapproved research and can never be reported or published as research data.

* All changes or amendments to the above-referenced protocol require review and approval by the IRB BEORE implementation.

Adverse Reactions/Unexpected Events (AR/UE) must be submitted on the appropriate form within the timeframe specified in the IRB Administration Office Policy (http://www.irb.wayne.edu/policies-human-research.php).

NOTE:
1. Upon notification of an impending regulatory site visit, hold notification, and/or external audit the IRB Administration Office must be contacted immediately.
2. Forms should be downloaded from the IRB website at each use.

*Based on the Expedited Review List, revised November 1998
APPENDIX C

Copyright License Agreement for Chapter 1

<table>
<thead>
<tr>
<th>Title</th>
<th>The balancing act – PPAR-γ’s roles at the maternal-fetal interface</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author</td>
<td>Leena Kadam, Hamid Reza Kohan-Ghadir, Sascha Drewlo</td>
</tr>
<tr>
<td>Publication</td>
<td>SYSTEMS BIOLOGY IN REPRODUCTIVE MEDICINE</td>
</tr>
<tr>
<td>Publisher</td>
<td>Taylor &amp; Francis</td>
</tr>
<tr>
<td>Date</td>
<td>Mar 4, 2015</td>
</tr>
<tr>
<td>Copyright</td>
<td>Copyright © 2015 Taylor &amp; Francis</td>
</tr>
</tbody>
</table>

**Thesis/Dissertation Reuse Request**

Taylor & Francis is pleased to offer reuses of its content for a thesis or dissertation free of charge contingent on resubmission of permission request if work is published.

BACK  CLOSE WINDOW
April 7, 2017

Leena Kadam
Wayne State University
CS Mott Center for Human Growth and Development 275 E. Hancock
Detroit, MI 48201
Email: lkadam@med.wayne.edu

Dear Dr. Kadam,

The American Association of Immunologists, Inc., grants permission to reproduce the article, "An M1-like Macrophage Polarization in Decidual Tissue during Spontaneous Preterm Labor That Is Attenuated by Rosiglitazone Treatment," published in The Journal of Immunology, vol. 196, pp. 2476-2491, 2016, in your theses, contingent on the following conditions:

1. That you give proper credit to the authors and to The Journal of Immunology, including in your citation the volume, date, and page numbers.

2. That you include the statement:

   Copyright 2016. The American Association of Immunologists, Inc.

3. That permission is granted for one-time use only for print and electronic format. Permission must be requested separately for future editions, revisions, derivative works, and promotional pieces. Reproduction of any content, other than Figures and Figure Legends, from The Journal of Immunology is permitted in English only.

Thank you for your interest in The Journal of Immunology.

Sincerely,

Kaylene J. Kenyon, Ph.D.
Publication Director
The Journal of Immunology
APPENDIX E

Copyright License Agreement for Chapter 3

If you are a SAGE journal author requesting permission to reuse material from your journal article, please note you may be able to reuse your content without requiring permission from SAGE. Please review SAGE’s author re-use and archiving policies at https://us.sagepub.com/en-us/nam/journal-author-archiving-policies-and-re-use for more information.

If your request does not fall within SAGE’s reuse guidelines, please proceed with submitting your request by selecting one of the other reuse categories that describes your use. Please note, a fee may be charged for reuse of content requiring permission. Please contact permissions@sagepub.com if you have questions.
REFERENCES


cytotrophoblast differentiation/invasion is abnormal in pre-eclampsia. The American

63. Kliman HJ, Nestler JE, Sermasi E, Sanger JM, Strauss JF, 3rd. Purification,
characterization, and in vitro differentiation of cytotrophoblasts from human term

64. Waite LL, Person EC, Zhou Y, Lim KH, Scanlan TS, Taylor RN. Placental peroxisome
proliferator-activated receptor-gamma is up-regulated by pregnancy serum. The Journal

65. Tarrade I, Schoonjans K, Guibourdenche J, Bidart JM, Vidaud M, Auwerx J, Rochette-
Egly C, Evain-Brion D. PPARγ/RXRα heterodimers are involved in human CGβ
synthesis and human trophoblast differentiation. Endocrinology. 2001 Oct;142(10):4504-
14.

66. Schaiff WT, Carlson MG, Smith… SD. Peroxisome Proliferator-Activated Receptor-γ
Modulates Differentiation of Human Trophoblast in a Ligand-Specific Manner 1. Journal

67. Georges D, Lucie S, André M, Eric R, Julie L. Expression of cFABP and PPAR in
trophoblast cells: effect of PPAR ligands on linoleic acid uptake and differentiation.
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids.

68. Robson SC, Simpson H, Ball E, Lyall F, Bulmer JN. Punch biopsy of the human

69. Handschuh K, Guibourdenche J, Cocquebert M, Tsatsaris V, Vidaud M, Evain-Brion D,


106. McCarthy FP, Drewlo S, Kingdom J, Johns EJ, Walsh SK, Kenny LC. Peroxisome


111. Bach; RG, Brooks; MM, Lombardero; M, Genuth; S, Donner; TW, Garber; A, Kennedy; L, Monrad; ES, Pop-Busui; R, Frye; SFKRL, Investigators BD. Rosiglitazone and Outcomes for Patients with Diabetes and Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation. 2013.


113. Martin JA, Hamilton BE, Osterman MJK, Curtin SC, Mathews TJ. Births: Final Data for


144. Leonardini A, Laviola L, Perrini S, Natalicchio A, Giorgino F. Cross-Talk between


151. Lappas M, Permezel M, Rice GE. 15-Deoxy-Δ12,14-Prostaglandin J2 and Troglitazone Regulation of the Release of Phospholipid Metabolites, Inflammatory Cytokines and


Houston KD, Copland JA, Broaddus RR, Gottardis MM, Fischer SM, Walker CL.


183. He P, Li Y, Ding X, Sun Q, Huang Y, Gu H, Ni X. Expression of 15-


203. Hardison JL, Wrightsman RA, Carpenter PM, Lane TE, Manning JE. The chemokines CXCL9 and CXCL10 promote a protective immune response but do not contribute to
cardiac inflammation following infection with Trypanosoma cruzi. Infection and Immunity. 2006;74(1):125-34.


209. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARgamma promotes


Immunology and Cell Biology. 2014;92(9):799-809.


285. KnÖFler M. Critical growth factors and signalling pathways controlling human


306. Leach RE, Jessmon P, Coutifaris C, Kruger M, Myers ER, Ali-Fehmi R, Carson SA,


313. Benyo DF, Smarason A, Redman CWG, Sims C, Conrad KP. Expression of Inflammatory Cytokines in Placentas from Women with Preeclampsia. The Journal of


335. Fournier T, Handschuh K, Tsatsaris V, Evain-Brion D. Involvement of PPARγ in Human


ABSTRACT

THE ROLE OF PPARΓ IN PLACENTAL DEVELOPMENT AND DISEASE

by

LEENA KADAM

August 2017

Advisor: Dr. Sascha Drewlo

Major: Physiology (Reproductive Sciences Concentration)

Degree: Doctor of Philosophy

The placenta in mammals forms the maternal fetal interface serving as the source of nutrition for the fetus throughout gestation. It comprises of two major trophoblast lineages: (i) the decidua invading extra-villous trophoblast (EVT) and (ii) the placenta residing villous trophoblast (VT). The EVT’s invade the maternal endometrium to establish pregnancy and secure blood-flow to the implantation site. The VT villous trophoblast forms the main maternal-fetal exchange surface and ensures nutrient and gas exchange to facilitate growth throughout pregnancy. Additionally, both lineages are involved in immunological functions such as maintaining allogenic tolerance and regulation of immune cell activation at the maternal fetal interface. They also express pattern recognition receptors like TLR (toll-like receptors) and NLR (Nod-like receptors) involved in pathogen recognition. Activation of these receptors leads to an inflammatory cascade aimed at elimination of the pathogen which in severe conditions can lead to preterm birth (PTB) and even fetal death. Proper development of trophoblast cells is thus crucial for placental function and hence for a successful pregnancy. Indeed, pregnancy disorders like pre-eclampsia (PE), intra – uterine growth disorders (IUGR) and preterm birth (PTB) have all been associated with abnormal trophoblast differentiation. Interestingly, elevated levels of
systemic as well as placental inflammation is another feature commonly associated with these disorders. Localized inflammation (Chorioamnionitis) has been reported to be present in >85% spontaneous preterm births even in the absence of systemic inflammation. However, the potential effects of inflammatory pathways on placental function (and trophoblast differentiation) remain largely unexplored. Consequently, there is also less information available on molecular targets common to both these processes that can be used for development of therapeutic interventions.

The ligand activated transcription factor PPARγ has a known anti-inflammatory role and plays a crucial role in placental development. Abnormal levels of the receptor were also associated with disorders IUGR associated PE, GDM and even PTB. However, the potential role of PPARγ in regulation of the placental and systemic immune responses remains unexplored. Our preliminary studies in the mouse model of inflammation induced PTB showed that activation of PPARγ significantly reduced PTB and improved both placental and fetal weights. The current dissertation therefore aimed to evaluate PPARγ as the potential common link between inflammation and placental function. Based on our preliminary results, we hypothesized that PPARγ is an important modulator of placental immune responses and is as well involved in trophoblast function.

**AIM 1:** To determine the molecular mechanism of PPARγ mediated prevention of PTB in endotoxin induced PTB mouse model

In our preliminary studies, we observed that treatment with Rosiglitazone (specific agonist for PPARγ) significantly reduced pre-term birth in the mouse model for endotoxin (bacterial lipopolysaccharide) mediated inflammatory preterm birth. The current aim was designed to evaluate the mechanism involved. Our results revealed that activation of PPARγ via Rosiglitazone had anti-inflammatory effects at both systemic and local levels. We also reported that the endotoxin (LPS) increases inflammation by upregulating its receptor TLR4 and
contributes to oxidative stress by downregulating the anti-oxidant pathway. Rosiglitazone via PPARγ activation decreased the inflammatory cytokine levels in serum and downregulated activity of NF-κB pathway in macrophages at the maternal-fetal interface. It also upregulated expression of anti-oxidant pathway mediators NRF2 and HO-1 and reduced the expression of TLR4. We thus report for the first time, that PPARγ activation via Rosiglitazone prevents LPS induced preterm birth in mice by acting on inflammatory as well as anti-oxidative pathway.  

**AIM 2:** To determine the effects of LPS exposure and PPARγ induction on human trophoblast physiology

In our mice studies, we observed that endotoxin treatment caused reduction in placental weights suggesting inflammation mediated effects on mouse placenta. Since elevated inflammation is associated with approximately 30% of preterm deliveries in humans, we asked if inflammation had any effects on human placental function. Previous studies have focused on evaluating the inflammatory response of human placental trophoblast cells. However, the effects of inflammation on trophoblast cell differentiation and function remain comparatively unevaluated. Additionally, the potential anti-inflammatory effect of PPARγ in human placenta also remains unexplored. The current aim was designed to evaluate the effects of endotoxin exposure on the human trophoblast cell differentiation and function and the potential role of PPARγ in reversing these effects. Our results showed for the first time that inflammation alters trophoblast cell differentiation and function -- by downregulating expression of trophoblast differentiation proteins GCM1 and CG-β and reducing invasion -- which can be reversed by PPARγ activation.

**AIM 3:** To determine the role of PPARγ in differentiation of EVT and VT trophoblast lineages.

The data obtained in Aim 1 and Aim 2 highlighted the key role for anti-inflammatory activity of PPARγ in placental function and pregnancy in general. However, PPARγ is
implicated to be involved in placental development via pathways beyond inflammation. Previous studies and results presented in chapter 4 suggested a key role for PPARγ in trophoblast differentiation via regulation of GCM1 – transcription factor crucial for differentiation towards both trophoblast lineages. The first part of Aim 3 therefore focused on validating the PPARγ – GCM1 molecular axis. Our results showed that PPARγ transcriptionally regulated GCM1 expression by binding to its specific binding site in the GCM1 promoter. The second part of Aim 3 was designed to further delineate the role of PPARγ in differentiation towards the VT and EVT lineages. A crucial initial step was to develop a model to simultaneously study both lineages. In the current study, we established the model and conducted preliminary experiments for determining the specific role of PPARγ in trophoblast lineage differentiation.
AUTOBIOGRAPHICAL STATEMENT

LEENA KADAM

Education:
2013-present) PhD Candidate (Reproductive Sciences) Department of Physiology, School of Medicine, Wayne State University

2010 Master of Science in Biotechnology-Depart. Biotechnology, University of Mumbai, Mumbai, India

2008 Bachelor of Science in Biotechnology-Kischinchand Chellaram College, University of Mumbai, Mumbai, India

2007 Diploma Industrial Chemistry-Kischinchand Chellaram College, University of Mumbai, Mumbai, India

Awards:
2017 Pfizer President’s Presenter’s Award, Society for Reproductive Investigation

2017 Competitive Travel Award, Dept. Physiology, Wayne State University School of Medicine.

2016 3rd Place Poster, Wayne Day Dept. Obstetrics & Gynecology, Wayne State University School of Medicine.

2015 Competitive Travel Award, Dept. Physiology, Wayne State University School of Medicine.

2013 2nd Place Poster, Wayne Day Wayne Day Dept. Obstetrics & Gynecology, Wayne State University School of Medicine.

Publications (selected):
1. Kadam L, Kilburn BA, Singh A, Kohan-Ghadr HR, Baczyk D, Kingdom J, Drewlo S. PPARγ at the cross roads of inflammation and differentiation in the human placenta. (Manuscript in preparation)


5. 2;8(363):363re4. (*Equal contributors)


